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Abbreviations 
ACE   angiotensin-converting enzyme 
ACh acetylcholine 
ACN   acetonitrile 
ACR   aldosterone to cortisol ratio 
ACTH   adrenocorticotropic hormone 
AGT   Angiotensinogen 
Ang I   Angiotensin I 
Ang II   Angiotensin II 
ANP   atrial natriuretic peptide 
APA   aldosterone producing adenoma 
ARR aldosterone to renin ratio 
AT1   Angiotensin II type 1 receptor 
AVP   arginine vasopressin 
BAH bilateral adrenal hyperplasia 
BK   bradykinin 
BMI    body mass index 
 [Ca2+]i intracellular calcium 
CBG cortisol binding globulin 
CV   coefficient of variation 
DCM dichloromethane 
DIN   Deutches Institut für Normung (German Industry Norm) 
ECF   extracellular fluid volume 
ED50   Estimated Dose 50 
EDTA   ethylene diamine tetraacetic acid 
EH essential hypertensive 
ENaC   epithelial sodium channel 
HCO3- bicarbonate 
H2CO3 carbonic acid 
HPLC high performance liquid chromatography 
11β-HSD2   11β-hydroxysteroid dehydrogenase type 2 
IgG   Immunoglobulin G 
IHA idiopathic hyperaldosteronism 
JG   juxtaglomerular  
kDa   kilodalton 
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LOD   limit of detection 
LRH low renin hypertension 
mM   millimolar 
ml/min   milliliter per minute 
MeOH   methanol 
MR   Mineralocorticoid receptor 
NA noradrenaline 
ng/ml   nanograms per milligram 
nm   nanometers 
17-OHP 17-hydroxyprogesterone 
ODS   octadecylcylsilane 
PA   Primary aldosteronism 
PEG   polyethyleneglycol 
pg/ml   picograms per milligram 
PLA   plasma aldosterone 
POMC   proopiomelanocortin  
RP HPLC   reverse phase high performance liquid chromatography 
RT   room temperature 
Rt   retention time 
RAAS   Renin Angiotensin Aldosterone System 
RAS   Renin Angiotensin System 
RIA radioimmunoassay 
SA   salivary aldosterone 
SD   standard deviation 
SEM   standard error of the mean 
SF   salivary cortisol 
StAR   steroidogenic acute regulatory protein 
TRFIA   time-resolved fluorescence immunoassay 
UV ultraviolet 
ZG   zona glomerulosa 
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1. Introduction 
 
  The mineralocorticoid aldosterone  
 
 Adrenal cortex and production, mechanism of action 
 
 The steroid hormone aldosterone, synthesized in the outermost zone, of the adrenal 
cortex, the zona glomerulosa, has an essential role in electrolyte and fluid balance.  However, 
this hormone is also known to stimulate cellular hypertrophy, matrix formation, and cell death 
(White, 2003; Rocha et al., 2000).  Aldosterone is the final endocrine signal in the renin 
angiotensin aldosterone system (RAAS) (Booth et al., 2002).  As for all steroid hormones, the 
substrate for aldosterone synthesis is cholesterol.  The early pathway of aldosterone biosynthesis 
involves the initial enzymatic step converting cholesterol to pregnenolone.  The 
mineralocorticoid biosynthetic pathway itself begins at the level of progesterone which is 21 
hydroxylated by CYP21A2 to 11-deoxycorticosterone (Figure 1).  The next two steps involve 
CYP11B2 for the conversion of 11-deoxycorticosterone to corticosterone and finally the “late 
pathway” of aldosterone biosynthesis of corticosterone to aldosterone (Williams, 2005). 
Aldosterone is designated a mineralocorticoid because its actions involve reabsorption of 
Na+ and release of K+ by epithelial cells of the kidney, particularly in the distal convoluted tubule 
and cortical collecting duct, as well as in the intestine, colon and salivary glands. (Weber, 2001).  
Aldosterone’s effect on sodium transport occurs in three phases, starting with the first, latent 
phase, where there is no increase in the transepithelial transport and lasts for only a few minutes 
up to one hour.  This non-genomic effect, occurs in, for example, smooth muscle.  The second 
occurs between 1 and 6 hours, and there is a rapid 4 to 6-fold increase in the sodium current.  In 
the final late phase, after 3 hours, there is an additional 2 to 4-fold increase in the sodium current, 
but this requires gene transcription and the formation of new sodium channel mRNA (Booth et 
al., 2002; LeMoëllic et al., 2004).  The classical, and longer term epithelial effects of aldosterone 
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on the mineralocorticoid receptor (MR) to retain Na+ and excrete K+ are genomic, whilst its 
acute 
 
Figure 1. Schematic diagram of steroid biosynthesis (reproduced from Dörner, 1999). 
 
effects on the vasculature are clearly non-genomic.  Some effects of the receptor activation, such 
as a central effect on blood pressure or cardiac fibrosis, have such complexity where the 
distinction between time courses, genomic or not, are not possible (Funder, 2006). 
Rapid, non-genomic effects of aldosterone are believed to act on the Na+/H+ exchange via 
another (type 2) receptor and a 2nd messenger system.  Several second messengers may be 
involved such as cAMP, inositol trisphosphate, and diacylglycerol.  In human mononuclear 
leucocytes for example, aldosterone increases intracellular levels of Na+, K+, and Ca2+ , leading 
to volume increases in these and endothelial cells (Lösel et al., 2004).  Changes in posture and 
blood pressure are rapid stimuli for aldosterone secretion which bring about direct 
vasoconstrictor effects.  These non-epithelial sites of MR activation, such as vascular walls, are 
protected from activation by cortisol by expression of the enzyme 11-β-hydroxysteroid 
MINERALOCORTICOIDS 
GLUCOCORTICOIDS 
SEX STEROIDS 
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dehydrogenase type 2 (11β-HSD2), which metabolizes glucocorticoids to products with reduced 
affinity for the MR, thus providing tissue specificity (Booth et al., 2002).  This is important for 
aldosterone’s acute, external rather than renal, blood pressure regulation effects.  Evidence for 
this comes from the analysis of the effects of the selective MR antagonist, eplerenone, whereby 
there was no correlation found between its hypotensive effect of MR blockade and levels of 
plasma K+ concentration, indicating its epithelial effects (Funder, 2006).    
On a long-term basis, aldosterone acts by penetrating the cell membrane and binding to 
the specific type 1 cytoplasmic receptor.  The hormone receptor complex moves to the cell 
nucleus, acts on nuclear DNA at the stage of transcription and initiates mRNA synthesis.  
Cytoplasmic proteins are then synthesized which may act by increasing luminal membrane 
permeability to sodium and potassium ions or by stimulating the Na+/K+-ATPase exchange pump 
in the serosal membrane.  An active exchange of sodium ions in the tubular lumen for potassium 
or hydrogen ions in the peritubular fluid, is believed to occur at a ratio of two sodium ions for 
one potassium.  Hydrogen ion excretion can also be influenced.  In the excess presence of 
mineralocorticoids metabolic alkalosis may develop due to extreme loss of hydrogen ions as a 
consequence of increased re-absorption of sodium (Laycock & Wise, 1996).  As a consequence 
of the exchange of K+ or H+ for Na+, plasma sodium concentration rises, osmoreceptors in the 
anterior hypothalamus are stimulated, vasopressin is released from nerve terminals in the 
neurohypophysis, and water reabsorption from collecting ducts is stimulated.  Water follows the 
movement of Na+ via osmosis, so that chronic blood volume, and thus blood pressure, are 
established.  When the plasma solute concentration is restored to normal and the extracellular 
fluid (ECF) volume has increased, then the osmotic stimulus for vasopressin ceases (Booth et al., 
2002).   
Even in the case of primary aldosteronism, ECF volume will not increase more than 15%, 
avoiding the occurrence of an oedema due to the existence of an ‘escape mechanism’ (Laycock 
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& Wise, 1996).  In heart failure however, mineralocorticoid escape does not occur and even 
relatively low levels of aldosterone can cause sodium retention and volume expansion (Williams, 
2005).  The major physiological importance of the aldosterone system is to prevent loss of salt 
and water during periods of dietary sodium deprivation. (Weber, 2001), although just as 
important is aldosterone’s role in maintaining potassium ion plasma concentration. 
 
1.1.2.  Control of release of aldosterone 
  
 Various factors control the release of aldosterone such as plasma sodium and potassium 
concentrations and aldosterone works constantly to keep these stable.  A 10% decrease in sodium 
or a 10% increase in potassium stimulate the release of aldosterone by direct effects on the 
adrenal cortex.  Potassium is a major physiological stimulus to aldosterone production and 
conversely aldosterone’s ability to increase K+ in the urine, feces, sweat and saliva secretion 
means it is integral to K+ homeostasis.  Aldosterone thereby serves to prevent hyperkaleamia 
during periods of high potassium intake. (Weber, 2001).  Aldosterone excess, on the other hand, 
will lead to potassium loss and hypokalemia.  Sodium adaptation is more complex, and it 
involves plasma volume changes as well as the Renin Angiotensin System (RAS), as discussed 
above.  Although Angiotensin II (Ang II) is thought to be the main and final stimulus for the 
production of aldosterone in response to Na+ deficiency, changes in the body’s sodium content 
may also be affected by other mediators such as inhibitory stimuli from atrial natriuretic peptide 
(ANP) or a high extracellular sodium concentration (Müller 1995).  Furthermore, the sensitivity 
of the zona glomerulosa (ZG) to different stimuli changes during different amounts of sodium in 
the body.  The regulatory loops are equally as important in maintaining aldosterone secretion 
high when nutrition is sodium deficient and high in potassium or vice versa.  Potassium and 
sodium concentrations and the RAS are all regulated by direct negative  feedback loops in 
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contrast to other factors influencing aldosterone secretion such as ANP or serotonin which are 
not.   
 
 
Figure 2.  Regulation of aldosterone secretion in the mammalian organism (Müller, 1995). 
 
 Adrenocorticotropic hormone (ACTH) from the adenohypophysis, or anterior pituitary, is 
another such secretagogue that has both steroidogenic and tropic effects on the adrenal gland.  
The short-term action of ACTH involves the conversion of cholesterol to pregnenolone and 
therefore has a positive effect on aldosterone production as a short-term stimulator.  This 
response is usually to stress, leading to production by zona glomerulosa cells in vitro as well as 
by the adrenal gland in vivo.    The aldosterone stimulating effect of ACTH is thought to be 
transient.  Prolonged or repeated  administration of pharmacological doses in humans and 
animals has shown that plasma aldosterone returns to basal within a few days, in contrast to 
cortisol which remains elevated (Müller 1995, Gallo-Payet et al., 1996).  On a long-term basis, 
ACTH has chronic effects that stimulate the biosynthesis of enzymes involved in steroidogenesis 
by increasing mRNA levels  and by making more cells capable of conducting steroidogenesis 
(Vinson, 2003).   
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 The rapid translocation of cholesterol to the inner membrane of the mitochondria is a 
rate-limiting step in the acute regulation of aldosterone production.  ACTH works in conjunction 
with a factor called steroidogenic acute regulatory protein (StAR) to enhance this step.  This is 
important since steroidogenic cells store minimal amounts of hormones, so that hormone levels 
are regulated primarily at the level of synthesis.  The enzymes involved in the later steps of 
steroidogenesis are zone specific, so that the cells of the zona glomerulosa express the enzyme 
CYP11B2, producing aldosterone.  The long-term regulation of aldosterone by K+ or Ang II also 
involve stimulation of expression of this enzyme (Peters et al., 2006).  
 ANP is a hormone involved in sodium ion regulation which has an inhibitory effect on 
renin, and ultimately on aldosterone release, on catecholamines and on vasopressin.  The main 
stimulus for its release being the stretching of myocytes, the site of its production, by increased 
atrial volume.  ANP causes increased excretion of salt and water by the kidneys and a decrease in 
arterial blood pressure.  Arginine vasopressin (AVP), a hormone originating from the posterior 
pituitary, has been thought to suppress renin secretion and thereby aldosterone secretion 
(Laycock & Wise, 1996).  However there is increasing evidence that locally produced 
neurotransmitters and neuropeptides including AVP can participate in the regulation of 
steroidogenesis, and animal studies have shown that AVP produced within the adrenal gland can 
stimulate corticosteroid secretion via a paracrine mechanism.  More recently, the presence of 
AVP secreting cells has been shown in the human adrenal gland and a direct stimulatory effect of 
AVP has been shown on the production of aldosterone in man.  AVP-induced stimulation of 
human adrenocortical cells can be accounted for by activation of vascular V1a receptors 
(Perraudin et al., 2006, Guillon et al., 1995).  Catecholamines have been shown to stimulate 
mineralocorticoid production through activation of adrenergic β-receptors that are, like the 
ACTH receptor, positively coupled to adenylyl-cyclase  (Perraudin et al., 2006). 
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1.1.3.  Diurnal variation 
 
 The secretory pattern of aldosterone is influenced by ACTH and by PRA and there is 
evidence to show it has a circadian rhythm but with marked variations, making it difficult to 
define a normal range (James et al., 1976; Few et al., 1984; Few et al., 1986, Takeda et al., 
1984).  Peak secretion times for aldosterone and cortisol are significantly correlated according to 
some, with aldosterone secreted mainly at 2:15 and 6:30 am, under controlled conditions of 
sleep, posture and diet, preceding the secretion of cortisol by about an hour and following the 
secretions of melatonin and PRA.  The study demonstrating these times by Hurwitz (Hurwitz et 
al., 2004) also confirmed the general peak times of aldosterone and cortisol previously shown by 
others and showed that prolonged bed rest does not change the intrinsic circadian rhythm or 
diurnal rhythms of the components of the RAAS, an observation which has also previously been 
reported for cortisol (Chavarri et al., 1977).  Peak secretion times for aldosterone have been 
reported at around 10am by Takeda (Takeda et al., 1984) and between 8am and 11am by Few et 
al (Few et al., 1987).  In a study by Katz (Katz et al., 1972) with frequent sampling it was 
observed that aldosterone, PRA and cortisol secretions are synchronous, they occur during late 
sleep and soon after rising and may depend on ACTH when the postural stimulus to renin is 
absent.  A few years later the same authors reported that an external factor may control both 
ACTH and aldosterone, suggesting that renin is not the strongest determinant of aldosterone 
secretion (Katz et al., 1975).   
 Renin is inhibited when salt and water are taken in and activated when they are not.  
Therefore there can be periodicity in the activation of this system throughout the day depending 
on food intake, or over the course of many days, when periods of starvation are exchanged with 
the consumption of food and water.  There is conflicting evidence on whether renin is driven by 
a sleep-wake cycle or occurs as an endogenous, circadian process independent of posture and 
diet (Hurwitz et al., 2004). 
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1.1.4.  The classical and local tissue Renin-Angiotensin-Aldosterone System  
  
 The most important control mechanism for the release of aldosterone is the RAAS. 
Classically, the RAAS begins with the synthesis of renin, a glycoprotein enzyme of 44kDa, 
which is released by exocytosis from juxtaglomerular (JG) cells lining the afferent renal 
arterioles and nearby macula densa cells of the distal tubule (Carey & Siragy, 2003). Stimuli for 
the release of renin include decreased renal perfusion pressure, with the decrease in arterial blood 
pressure of the afferent arterioles being directly detected by JG cells or by adjacent renal 
vascular baroreceptors.  Other stimuli such as haemorrhaging, salt and water loss, or abnormally 
long pooling of the blood in the legs when an upright posture is taken, in the case of postural 
hypotension, also stimulate release due to falls in blood pressure (Weber, 2001).  Another 
suggested mechanism is via the direct effects of sympathetic stimulation to the kidneys.  In this 
case JG cells may be innervated by adrenergic nerve fibers or by circulating catecholamines 
which may stimulate release by acting on α-receptors present on the cells (Laycock & Wise, 
1996).   
 Following stimulation of the JG cells renin is released and it cleaves circulating 
Angiotensinogen (AGT) produced by the liver, forming the decapeptide precursor, Angiotensin 
I, which is biologically inert.  AGT is also synthesized and released in other tissues including the 
heart, vasculature, kidneys and adipose tissue.  Angiotensin-converting enzyme (ACE), bound to 
the plasma membrane of endothelial cells, cleaves 2 amino acids from Angiotensin I to form 
biologically active Angiotensin II (Ang II). Ang II is itself important in maintaining circulatory 
homeostasis.  When it is present in large amounts it is a potent vasoconstrictor, constricting 
arterioles within the renal and systemic circulation.  A further role of ACE is to metabolize 
bradykinin (BK), an active vasodilator and natriuretic substance, into the inactive metabolite 
BK(1-7).  ACE therefore, not only increases the production of a vasoconstrictor, but at the same 
time also degrades a vasodilator (Carey & Siragy, 2003). 
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The role of Ang II in the RAAS is to stimulate the ZG to produce aldosterone thereby promoting 
the reabsorption of Na+ in proximal segments of the nephron.  Ang II is the principal stimulator 
of aldosterone production when intravascular volume is reduced (Weber, 2001).  Blood pressure 
and Ang II are inversely related so that when blood pressure is decreased, Ang II production 
increases (Booth et al., 2002).  Most of the cardiovascular, renal, and adrenal actions of Ang II 
are mediated by the type 1 receptor (AT1) which is positively coupled to protein kinase C and 
negatively coupled to adenylyl cyclase.  These receptors are responsible for mediating vascular 
smooth muscle contraction, aldosterone secretion, dipsogenic responses, renal sodium 
reabsorption, and tachycardic responses (Carey & Siragy, 2003).  Aldosterone’s response to Ang 
II depends on sodium balance.  Aldosterone release in response to Ang II is increased within 
minutes from adrenal cells in vitro, and under sodium depletion the same amount of Ang II 
induces a greater increase in aldosterone production than under sodium load (Peters et al., 2007). 
Angiotensin and aldosterone are further involved in endocrine functions to do with circulatory 
homeostasis, namely the coagulation of blood, through increased production of plasminogen-
activator inhibitor type1 and the activation of platelets, as well as the stimulation of thirst 
(Weber, 2001).  Regarding thirst stimulation, a brain renin-angiotensin-system with all the 
relevant components has been identified (Parsons & Coffman, 2007).  Other sites of action 
include the regulation of inflammatory processes, by stimulating cytokines, inflammatory-cell 
adhesion and activation of macrophages, and reparative processes by inducing growth of 
fibroblasts and synthesis of fibrillar collagens to aid the formation of scar tissue, after tissue 
injury (Weber, 2001). 
 In recent years studies have started to focus on the existence of the RAS locally within 
tissues and demonstrated its importance within the brain, heart, peripheral blood vessels, adrenal 
glands, and the kidney (Muller 1997; Engeli et al., 2000; Dostal, 2000; Takeda et al., 2004; 
Gomez-Sanchez et al., 2004; MacKenzie et al., 2000).   
 19
Local Renal Aldosterone system Investigators in one study demonstrated the local expression of 
aldosterone synthase,  CYP11B2, gene as well as protein, and aldosterone production within the 
kidneys of normal rats (Xue & Siragy, 2005).  The authors confirmed their hypothesis of the 
occurrence of these components of the RAAS by showing the presence of aldosterone in kidneys 
of adrenalectomised animals, and showed an increased renal aldosterone synthase expression 
after a low-sodium diet as well as after Ang II administration.  They additionally confirmed that 
the AT1 receptor regulates the production of this enzyme locally in the kidney by carrying out 
receptor blockade which reversed the Ang II up-regulation of the CYP11B2 enzyme.  The study 
established that aldosterone production and its receptors exist in close proximity, pointing to a 
local renal autocrine or paracrine aldosterone system influencing renal function.    
Local Adrenal RAS  Adrenal renin and angiotensinogen mRNA and their formation within the 
adrenal gland ZG has proven the existence of a local adrenal RAS.  Adrenal renin concentrations 
increase by sodium restriction and high-potassium diets, and nephrectomy increases adrenal 
renin via increased serum potassium.  In zona glomerulosa cells where there has been inhibition 
of ACE or the AT1 receptor, aldosterone stimulation by ACTH or potassium is also hindered 
(Gupta et al., 1995).  However, it is not certain whether the adrenal RAS works as an 
autocrine/paracrine system to upregulate adrenal responses to Ang II originating from the 
systemic circulation, or if it has a role in pathophyiological disease states.   
Cardiac RAS  Evidence now exists that all the components of the RAS necessary for the 
production of Ang II exist, and that Ang II is in fact produced, within the heart.  All of these 
components are distributed in myocardial fibroblasts and cardiomyocytes, the endothelium and 
vascular smooth muscle of coronary arteries and veins.  Furthermore, renin, angiotensinogen, 
ACE and Ang II receptors are all present in the myocardium (Dostal & Baker, 1999).  However, 
though myocardial concentrations of renin and angiotensinogen are at 1-4% of those in plasma, 
the levels of Ang I and II are over 100-fold those of plasma and the conversion is said to occur 
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via a heart chymase instead of ACE, which does not degrade BK, converting 90% of 
Angiotensin I (Ang I) to Ang II.  Controversy still exists as to whether local Ang II production in 
the heart acts as a paracrine or autocrine regulator of cardiac function.  Evidence for the 
possibility of the existence of a vascular RAS has shown that renin is probably not synthesized 
locally in blood vessel walls, because renin was not detectable by RT-PCR but rather that it is 
taken up by the endothelium.  It is recognized,  on the other hand, that Ang II is generated by 
endothelial and endocardial cells so that the endothelium mediates vascular Ang II formation by 
the cellular uptake of renin (Carey & Siragy 2003). 
 
1.1.5.  Aldosterone and endocrine hypertension 
  
 Aldosterone promotes hypertension, stroke, cardiac fibrosis, ventricular hypertrophy, and 
myocardial necrosis (Struthers & MacDonald, 2004), which is why understanding the regulation 
of its production is an essential goal in understanding the pathophysiology of cardiovascular 
diseases.  Recent evidence has revived interest in aldosterone and its role in congestive heart 
failure (Adler & Williams, 2007).  The importance of aldosterone in blood pressure homeostasis 
is particularly important since every known form of hereditary, or Mendelian, hypertension in 
humans results from anomalous aldosterone signaling or the increased activity of its final 
effectors, the luminal epithelial sodium (ENaC) and K+ channel and the serosal Na+/K+-ATPase 
(Booth et al., 2002). 
 Hyperaldosteronism describes a state of sustained high secretion of aldosterone from one 
or both adrenal cortices and can be subdivided into two categories.  In Primary aldosteronism 
(PA), the hyperfunction is due to autonomous adrenal secretion of excessive aldosterone, while 
in the secondary form the hypersecretion is due to increased levels of Ang II due to high plasma 
renin activity which may be occurring due to a variety of causes.  The clinical picture is different 
in each case.  In PA the clinical symptoms are those due to the pathophysiological actions of 
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aldosterone itself while in the secondary various causes of increased renin determine the clinical 
picture (Laycock & Wyse, 1996).  Individuals with increased aldosterone are more prone to 
developing premature vascular diseases and therefore early diagnosis and treatment are essential.  
PA is the most common form of mineralocorticoid hypertension.  It is increasingly common in 
‘essential’ hypertension, present in about 10% of all hypertensives.  Its diagnosis in hypertensive 
individuals is targeted by therapy such as by the removal of an adenoma or treatment with 
mineralocorticoid receptor antagonists (Schirpenbach & Reincke, 2007; Mulatero et al., 2005).  
Though hypokalemia was thought to be a mandatory finding in PA, studies later confirmed that 
most patients with PA are in fact normokalemic (Mattsson & Young, 2006; Schirpenbach & 
Reincke, 2006). 
 The two main causes of PA are due to aldosterone producing adenomas (APAs) in the 
classical Conn’s syndrome, and bilateral adrenal hyperplasia (BAH), also known as bilateral 
idiopathic hyperaldosteronism (IHA) (Mattsson & Young, 2006).  Other causes have also been 
identified, such as glucocorticoid remediable aldosteronism, under the control of ACTH, and 
adrenal carcinomas.  APAs are unilateral tumours of the adrenal cortex which result in 
autonomous secretion of aldosterone, thought to be responsive to ACTH as opposed to Ang II 
although recently it has been suggested that up to 50% also respond to Ang II (Stowasser et al., 
2001).  In the case of BAH, both adrenals secrete high amounts of aldosterone in response to 
Ang II.  Therefore the disorder may be considered an exaggeration of normality where excessive 
amounts of aldosterone are secreted in response to dominating levels of Ang II (Mulatero et al., 
2005).     
 In PA, the mechanisms involved in the maintenance of autonomous aldosterone secretion 
in the absence of circulating Ang II remain to be elucidated.  AVP may also play a role in the 
pathogenesis of aldosterone hypersecretion.  The presence of AVP-secreting cells in APA tissue 
suggests that AVP released by intratumoral cells may exert an autocrine / paracrine stimulation 
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on the secretion of aldosterone.  Indeed, data indicate that SR 49059, an AVP selective non-
peptidic receptor antagonist, modifies tumor cell sensitivity to different stimuli including 
posture-sensitive hormones and ACTH (Perraudin et al., 2006). 
 A wide range of percentages has been reported for cases of PA among hypertensives 
from different centers, mostly due to the definition of the selection criteria for screening and 
confirmation.  The most commonly used tests for screening the presence of PA is the upright 
serum aldosterone to upright plasma renin activity or plasma renin concentration ratio (ARR).  
According to a review by Montori and Young (Montori & Young, 2002) the ARR is the primary 
test of choice for predicting primary aldosteronism.  This test is carried in the morning in order to 
avoid influences by diurnal rhythms of aldosterone and is dependable because it can diagnose 
aldosteronism even if aldosterone or renin are within normal values of the physiological range.  
Furthermore, this test can be carried out even when on anti-hypertensive medication.  Due to the 
fact that low renin hypertension (LRH) can also produce an elevated ARR, there also needs to be 
a normal to high or pathologically high aldosterone value in order to confirm diagnosis of PA.  
Several factors are involved, however, in assigning an appropriate cut-off value for the ARR, 
such as the method used for the respective aldosterone and renin measurements. Giacchetti et al., 
for example, suggest a value of 40 giving best sensitivity and specificity, using the solid phase 
radioimmunoassay (RIA) kit (Biodata Diagnostics, Rome, Italy) for serum aldosterone and PRA 
was measured as the generation of Ang I in vitro also using a commercially available RIA kit 
(Radim, Rome, Italy).  Furthermore, the role played by the nature of the cohort, in addition to 
false negatives due to ACE inhibitors, Angiotensin II and aldosterone receptor antagonists, and 
false positives due to β-blockers and excess dietary Na+ intake all need to be taken into account 
(Schirpenbach & Reincke, 2006; Weinberger & Fineberg, 1993; Giacchetti et al., 2006).   
 Young in 2003 suggested that patients with hypertension and hypokalemia, and most 
with treatment-resistant hypertension should undergo screening for PA with the ARR and that a 
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high ratio is a positive screening test which warrants further confirmatory testing (Young, 2003).  
Dynamic tests typically used for confirmation of diagnosis of PA include the angiotensin-
converting enzyme inhibitor captopril or the angiotensin receptor blocker losartan, in order to 
test the sensitivity of the adrenal gland to physiological and pharmacological stimuli. The high 
salt diet or saline infusion test, the deoxycorticosterone acetate suppression test, and the longer 4-
day fludrocortisone suppression test are also used (Giacchetti et al., 2006; Valloton, 1996).  The 
posture test, which has been widely used to discriminate between APA and BAH, has been found 
to be less reliable than previously thought since Ang II responsive adenomas have been found to 
respond to posture in a way that resembles BAH (Espiner et al., 2003).   
 In order to distinguish the subtype of PA tests such as the upright posture test, imaging of 
the adrenal glands, and adrenal venous sampling are used.  In the upright posture test a serum 
aldosterone increase of 30% in upright posture, compared to supine, points to diagnosis of IHA 
while absence of a significant increase in response to posture points to the presence of APA 
(Giacchetti et al., 2006).  Cortisol is also measured so that an increase after posture against the 
diurnal rhythm of cortisol renders the test invalid (Schirpenbach & Reincke, 2006).    Adrenal 
vein sampling is used in the decision-making process leading to surgical intervention, but there 
are conflicting reports also arising from this method.  Some studies exist showing its importance 
in identifying contralateral adrenal suppression to localize the abnormal gland  while others 
report no discriminating ability (Doppman et al., 1992; Rossi et al., 2001; Espiner et al., 2003).  
Diagnosis of an adenoma can be made upon determination of aldosterone excess from one of the 
adrenal glands while there is suppression of the contralateral gland. 
 Patients with APAs have more severe hypertension, more frequently present 
hypokalemia, have higher plasma aldosterone (>25ng/dl), higher urinary aldosterone 
(>39µg/24hours), and in general are younger (<50 years) than those with idiopathic 
hyperaldosteronism (IHA) (Young, 2003).  The study by Giacchetti (Giacchetti et al., 2006) was 
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in agreement with these findings, plasma K+ levels were lower and urinary aldosterone higher in 
APA compared to IHA, while ARR’s did not differ between the two subtypes.  After a 4-hour 
saline infusion suppression test, serum aldosterone was higher in PA patients taking part in that 
study than in the essential hypertensives (EHs), but again there was no discrimination between 
APA and IHA.  Accordingly, plasma K+ was found lower in PA than in EHs, while urinary 
aldosterone and the ARR were higher.  The authors further showed the importance of evaluating 
the serum aldosterone to cortisol ratio before and after a 4-hour saline infusion test to exclude the 
possibility that the aldosterone levels are being affected by ACTH stimulation  due to circadian 
or stress-related factors.  APA patients have a higher aldosterone to cortisol ratio at the end of the 
test due to the independently high production of aldosterone which remains unaffected by the 
stimuli coming from the RAS or by  ACTH stimulation. 
 
 Saliva and monitoring of hormones 
 
 Saliva is a biological fluid containing many hormones, drugs and antibodies of interest, 
which is readily available and can be collected non-invasively.  An extensive amount of research 
has been carried out showing the possibility of utilising saliva as a diagnostic tool.  There are 
many distinct advantages of using saliva over serum as the diagnostic medium, mainly that 
whole saliva is easily available for non-invasive collection and analysis by individuals with 
limited training without the need for special equipment and, with certain devices, may be stored 
at ambient temperatures for extended periods.  The nature of salivary collection means that 
multiple specimens can be collected from an individual, providing the further advantage of 
monitoring over longer periods of time, an important factor especially in the study of steroid 
hormones which have diurnal and monthly variations.  Saliva may be used to monitor the 
presence of hormones, drugs, antibodies, micro organisms and ions.  It has been analysed for use 
in monitoring of drug pharmacokinetic and metabolic studies, drug abuse testing, assessment in 
 25
endocrine studies such as testosterone in males (Tschop et al., 1998) and progesterone in 
females, and virus diagnosis of antibodies against for example measles, rubella, and mumps 
viruses (Hofman, 2001; Kaufman & Lamster, 2002).  
 
 Anatomy and physiology of the salivary gland 
 
 There are three pairs of salivary glands, the parotid, the submandibular and sublingual.  
Saliva secreted from the largest gland, the parotid, is serous or watery, whereas the 
submandibular produces a mixture of mucous and serous fluids and saliva from the smallest, the 
sublingual gland, is predominantly mucous due to the glycoprotein content. The salivary gland is 
composed of secretory end pieces, acini, and a branched ductal system (Figure 3).  The secretory 
end pieces are supported and enveloped by a group of contractile myoepithelial cells which help 
to propel saliva into the ductal system (Edgar et al., 2004).  A salivary gland itself can consist of 
a variation of end pieces comprised of mucous or serous cells and the lumen which is the start of 
the ductal system.  There are three types of ducts through which the fluid passes, the intercalated, 
striated and excretory ducts (Höld et al., 1995).  
Modified interstitial fluid originating from blood in the capillaries surrounding the acinar 
Figure 3.  Anatomy of the salivary gland. 
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cells is secreted into the lumen and is then further modified within the ducts.  Ion exchange takes 
place in the striated ducts changing the solution from an isotonic to a hypotonic one, and 
excretory ducts further modify the fluid before it enters the mouth.  Before a substance can enter 
the salivary duct, however, it must pass the capillary wall, the basement membrane and the 
membrane of the glandular epithelial cells, the rate-limiting step occurring at the latter lipophilic 
layer of the epithelial cell membrane.  For this reason, saliva is not simply an ultrafiltrate of 
plasma, but a complex fluid formed by passive diffusion, ultrafiltration through pores in the 
membrane, or by pinocytosis (Caddy, 1984).  Furthermore, adjacent acinar cells within the end 
piece are coupled by gap junctions and these allow the transcellular exchange of ions and small 
molecules.  Small molecules of a molecular weight up to 200Da can be transported via 
ultrafiltration (Madara, 1988). 
 
1.2.2.  Mechanisms of Innervation and Secretion 
Salivary gland secretion is controlled mainly by parasympathetic nerve supply, 
originating from salivary nuclei at the juncture between the pons and the medulla, but also by the 
sympathetic nervous system, although to a lesser extent.  Parasympathetic innervation is 
activated by taste and mechanical stimuli from the tongue and other areas of the mouth via 
afferent sensory nerve fibres, the facial (VII) and glossopharyngeal (IX), to the solitary nucleus.  
To innervate the glands themselves, efferent pathways arising from the facial nerve, and via the 
submandibular ganglion, release acetylcholine (ACh) at the acinar cells of the sublingual and 
submandibular gland.  Similarly, efferent parasympathetic pathways of the glossopharyngeal 
nerve via the otic ganglion release ACh and innervate the parotid gland.  Sympathetic 
stimulation affects more the salivary composition itself by increasing exocytosis from certain 
cells, which is also influenced by many androgen, oestrogen, glucocorticoid and other peptide 
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hormones.  Sympathetic innervation regulates secretion of macromolecules via the release of the 
neurotransmitter noradrenalin (NA) (Turner & Sugiya, 2002).   
 
1.2.3.  Factors influencing composition and flow rate 
Saliva leaving the end piece lumen is isotonic with plasma.  As the fluid moves down the 
striated duct, sodium and chloride are reabsorbed, and potassium, bicarbonate and lithium are 
secreted into saliva.  However, because the ductal membranes are relatively impermeable to 
water, the saliva becomes hypotonic as it moves down the duct (Ganong, 2003; Vining et al., 
1983).    The striated ducts transport electrolytes from the primary saliva by active transport so 
that when salivary flow rate is slow it is able to modify the composition of saliva greatly and in 
stimulated, high, flow rates the saliva resembles more the primary saliva coming from acinar 
cells (Edgar et al., 2004).  
The contribution to whole saliva from each gland varies according to the level of 
stimulation. Un-stimulated saliva, in the absence of exogenous stimuli from taste or chewing, 
consists of 25% parotid, 60% from the submandibular, 8% from the sublingual, and 8% from the 
minor mucous glands and also contains gingival crevicular fluid, epithelial cells, bacteria, 
leukocytes, blood and viruses.  In stimulated saliva the parotid contribution rises to 50%, the 
submandibular to 35%, and the sublingual and minor mucous contributions remain at 8% (Edgar 
et al., 2004). 
Normal flow rates are between 0.3 and 0.4ml/min in un-stimulated and between 1.5 to 
2.0ml/min in stimulated states, with a maximum flow rate of 7ml/min after masticatory or 
gustatory stimuli.  A total of 0.6 to 1.5 litres of saliva are secreted per day.  Because of the 
circadian rhythm of flow rate, measurements which are repeated should be taken at the same 
time of day. Flow rate is greatly influenced by the degree of hydration, so that when body water 
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content is reduced by 8% the salivary flow decreases to almost zero, and by body posture so that 
in a standing person flow rate is higher than when lying down or when seated (Ganong, 2003). 
The pH of saliva depends on the bicarbonate concentration, and with increasing flow 
rates pH, bicarbonate (HCO3-), chloride and sodium ions, and proteins increase (Dawes & 
Kubieniec, 2004).  The ionic composition of saliva, when flow rate is constant, depends on 
duration of stimulation and circadian rhythms.  Circadian changes in the mineralocorticoid  
aldosterone plasma concentration probably account for the circadian rhythms in salivary Na+, K+, 
and Cl- ion concentrations.  The acrophase in the secretory rhythm of these ions fits in with the 
morning to noon-time acrophase of plasma aldosterone, thought to be the steroid with the 
greatest influence on electrolyte composition. Furthermore, authors have shown that salt 
restriction as well as injection of aldosterone can cause reductions in salivary sodium 
concentrations (Dawes, 1972; Pawan, 1955). 
Parameter Mixed Saliva Plasma 
Volume 500-1500ml/day 4.3% body weight 
Rate of Flow 0.6 (0.1-1.8) ml/min  
pH 6.7 (5.6-7.9) 7.4 
% Water 98 (97-99.5) 91.5 (90-93) 
Total protein (g/dl) 0.3 (0.15-0.64) 7.3 (6-8) 
Albumin  (g/dl)  4.5 (4-5) 
Mucin (g/dl) 0.27 (0.08- 0.6)  
Amino acids  (mg/dl) 0.1-40 0.98 
Potassium (mmol/l) 8-40 3.5-5.5 
Sodium (mmol/l) 5-100 135-155 
Calcium (mmol/l) 1.5-2 4.5-5.2 
Phosphate (mmol/l) 5.5-14 1.2-2.2 
Chloride (mmol/l) 5-70 100-106 
Cholesterol (mg/dl) 7.5 (3-15) 150-300 
Table 1. Correlation of saliva to plasma (Ritschel and Thompson, 1983) 
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The concentration of protein in saliva is low, at about 1/13th that of plasma, 
approximately 2mg/ml.  However many of these proteins found in saliva have important 
antimicrobial, lubricative and digestive functions (Edgar et al., 2004).  On the other hand, other 
proteins,  such as steroid binding proteins, are unable to pass from blood to saliva and this has 
drawn attention to the measurement of steroid hormones in saliva by those interested in 
measuring the non-protein bound fraction of that found in plasma (Höld et al., 1995).  Many 
proteins which are of clinical interest are present in saliva in trace amounts, such as 
choriogonadotropin, pituitary hormones, or albumin.  However the plasma to saliva ratio is 
around 10000:1 and the origin is probably due to contamination from plasma or gingival fluid.  
Some steroids conjugated to proteins, such as DHEAS and conjugated estrogens, are lipid 
insoluble but small amounts do enter the saliva through the tight junctions making these 
concentrations flow rate dependent and so small that they are easily affected by plasma or 
gingival fluid contamination.  These concentrations therefore provide no clinically useful 
indication of plasma concentrations.  In contrast, the lipid-soluble, un-conjugated steroids, such 
as cortisol, testosterone, and progesterone, enter saliva by passing through the cell membranes, 
are independent of flow rate, and concentrations give a close approximation of the plasma 
concentrations, giving a clinically useful index of unbound plasma levels (Vining et al., 1983). 
 
1.2.4.  Diagnostic application of saliva in measurement of steroid levels 
 
 Endocrine function is frequently evaluated and analyzed by looking at hormone levels in 
saliva.  The availability of this biological fluid and the non-invasive nature of its collection 
compared to blood sampling has made salivary steroid assays an appealing alternative.  Most 
steroid hormones are lipid-soluble and cross acinar cell membranes entering the saliva via 
passive diffusion, unlike other polar, small molecules (molecular weight up to 100-200) which 
enter via ultrafiltration through the tight junctions between cells (Quissell, 1993).  Hormones are 
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not believed to enter the saliva via active transport.  When a constant correlation exists between 
salivary and serum hormone levels, neutral steroids which can diffuse easily into saliva represent 
the free, non-protein-bound serum hormone level.  Conversely, protein hormones do not enter 
the saliva by passive diffusion due to their large size and would only be found in this fluid by 
contamination from serum due to oral wounds or from gingival crevicular fluid (Kaufman & 
Lamster, 2002). 
Cortisol is a typical example of a steroid hormone commonly used for diagnosis and the 
identification of patients with Cushing’s syndrome and Addison’s disease (Hubl et al., 1984), 
monitoring the hormone response to physical exercise (Lac et al., 1997) and the effects of stress 
(Obminski et al., 1997).  The levels of this hormone in saliva are highly correlated to plasma and 
not affected by changes in serum binding protein concentrations.  Importantly, because cortisol is 
the most prominent stress hormone and repetitive salivary sampling was not shown to induce its 
release (Kirschbaum & Hellhammer, 1989), it is fair to assume that this sampling method does 
not affect the levels of other steroid hormones either.  Cortisone is a hormone without 
diagnostically significant salivary levels which are actually higher than those found in serum, 
due to the enzyme 11β-HSD which is present in saliva and converts cortisol to cortisone (Vining 
& McGinley, 1986).  Salivary testosterone and dehydroepiandrosterone have also been measured 
at 1.5-7.5% of serum concentrations (Gaskell et al., 1980).  Similarly, estimation of salivary 
testosterone levels has been suggested for the assessment of testicular function (Walker et al., 
1980), behavioural studies of aggression, depression, and anti-social behaviour (Granger et al., 
1999), with a high correlation between salivary and serum-free testosterone concentrations (r = 
0.97) reported using a direct radioimmunoassay technique (Vittek et al., 1985).  A significant 
correlation (r = 0.78) has also been reported for levels of serum and saliva estradiol (Wang et al., 
1986) as well as salivary progesterone (r = 0.47–0.58), which both appear to reflect serum levels 
also during the menstrual cycle.  Use of salivary estriol levels was suggested for the assessment 
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of feto-placental function and progesterone for the prediction of ovulation and ovarian function 
(Lu et al., 1999).  A non-isotopic immunoassay for the determination of salivary 17-
hydroxyprogesterone (17-OHP) is a further example of the advantage provided by measuring this 
hormone in, for example, children where stress-related increases in the hormone can be avoided.  
Salivary 17-OHP levels are used to monitor metabolic control in children, adolescents and adults 
with congenital adrenal hyperplasia (Dressendorfer et al., 1998). 
Concentrations of protein hormones such as gonadotropins, prolactin, and thyrotropin, on 
the other hand, cannot be measured by salivary analysis due to their large size not allowing them 
to cross by passive diffusion (Vining & McGinley, 1986).   
Several studies have reported the correlation of salivary aldosterone, and its biological 
significance, compared to the levels found in plasma although a limited amount of work was 
done to show the clinical relevance.  Unlike cortisol, there is little evidence for a specific protein 
to transport circulating aldosterone.  An ultrafiltrate of plasma would contain up to 50% of 
circulating aldosterone, which, on an average sodium intake would secrete 0.1 to 0.7mmol per 
day.  75% of this aldosterone is inactivated by a single passage through the liver (Williams, 
2005).  In a study reporting an aldosterone-binding protein similar to cortisol binding globulin 
(CBG), increasing cortisol concentrations were shown to displace aldosterone (Davidson et al., 
1962), and other studies such as the one by McVie (McVie et al., 1979) have also shown that 
under circumstances of increased or decreased cortisol levels with ACTH or dexamethasone 
administration, free salivary aldosterone concentrations will also increase due to the presumed 
decrease in availability of CBG.  The aforementioned study speculates, however, that the 
hormone is not CBG as progesterone has a higher affinity for this protein than cortisol and also 
that the protein is not albumin, although progesterone can displace aldosterone from its binding 
sites (Davidson et al., 1962). 
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1.2.5.  Evidence for aldosterone in saliva until now 
 
Salivary hormones used to measure the non-protein bound, serum concentrations were 
first shown by Katz in the late 1960’s.  These authors showed that the sum of cortisol and 
cortisone in saliva would represent the free fraction of the plasma concentration and that this 
could also be possible in the case of salivary aldosterone.  McVie et al in 1979 tried to establish 
that saliva is a biological fluid which can be used to evaluate the concentration of free 
aldosterone by showing a correlation to urinary aldosterone excretion, plasma aldosterone and 
plasma renin activity.  They showed this under conditions of varying  dietary sodium, during 
ACTH stimulation and under dexamethasone suppression using a radioactive immunoassay.  
Previous investigators showed that protein bound aldosterone is between 30 and 90% and that 
changes in aldosterone binding were dependent on availability of corticosteroid binding globulin 
(Davidson et al., 1962, Meyer et al., 1961).  During dexamethasone administration, McVie et al 
found that the protein bound aldosterone increased, indicating increased available CBG.  During 
ACTH stimulation, protein bound aldosterone decreased, with low CBG.  This assay, though, 
which was of the first describing aldosterone in saliva, required large volumes (4ml) and 
involved both extraction and chromatographic purification of samples prior to use.  Importantly, 
baseline values of aldosterone were not detectable by the assay.    
Another assay which required solvent extraction was described by Hubl et al., in 1983.  
This group developed a solid phase enzyme immunoassay and looked at aldosterone levels 
before and after ACTH stimulation and in patients with Conn’s syndrome and Addison’s 
disease.  They found an overall level of 0.2 to 8.2ng/dl in normal subjects which increased by 
463% after ACTH.  Although the assay was non-radioactive, required relatively low levels of 
sample (200µl) and there was a good correlation with previously reported plasma values at the 
time, there was no continuation using this assay in further studies.   
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The following year, another group of investigators developed another ‘direct’ 
radioimmunoassay, with use of extraction by dichloromethane (DCM) to investigate plasma 
aldosterone (Few et al., 1984).  These investigators conducted many physiological tests showing 
daily fluctuations of aldosterone levels and concluded that the marked diurnal variation of the 
salivary aldosterone concentration made it difficult to define a normal range.  However, in 
normal un-stimulated subjects they did not encounter anything above 150pmol/l (54pg/ml) and 
suggest that this be the upper limit of healthy subjects.  When plasma levels fluctuated rapidly, 
such as in response to exercise, ACTH stimulation, standing, or morning levels, salivary levels 
retained a fairly constant relationship.  Lack of follow-up also exists with regards to this assay, 
possibly due to the sample volume of at least 1ml which was required and is not always easy to 
obtain from all subjects.  
A similar system was reported by another group shortly thereafter (Atherden et al., 
1985), also using a RIA employing extraction of samples.  This group also showed aldosterone 
levels rising in response to sodium restriction and lowest levels overall at 12pm.  The abundance  
of saliva to plasma concentrations was at approximately 26% both on low and normal sodium 
diets. Average values an hour after waking were found at 108pmol/l.  Salivary aldosterone 
reflected changes seen in plasma in response to time of day, sodium status, ACTH stimulation, 
and dexamethasone suppression.  An important observation taken from this study was that an 
hour after waking, with the participants still in the supine position, salivary aldosterone levels 
remained at the same level as when first waking up.  This fact is relevant to screening of 
subjects early in the morning where it has been suggested that levels may be unrepresentatively 
high, possibly due to reduced salivary flow rates, as was found in the case of testosterone, and 
can disprove this theory.  Therefore the potential of out-patient screening of hypertensive 
patients, which is the major goal in establishing such assays, may be recognized. 
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The most recent study to use salivary aldosterone levels in a diagnostic context was conducted to 
assess adrenocortical reserve by the simultaneous measurement of salivary cortisol and 
aldosterone (Cardoso et al., 2002). This study re-confirmed that the salivary aldosterone response 
to ACTH stimulation mirrors that seen plasma.  The investigators used a modification of a 
commercially available solid-phase RIA by increasing the sample volume to 400µl, twice that 
necessary for plasma assessment,  however.  In healthy subjects this study reports values of 
100pmol/l after ACTH stimulation, corresponding to 36pg/ml, with basal values at an average of 
35pmol/l.  There is a clear discrepancy in these results compared to the findings of previous 
groups who found basal concentrations of salivary aldosterone in healthy humans at 
approximately three-fold higher concentrations.  Many factors are involved and should be taken 
into account, especially when comparing commercially available to ‘in-house’ validated assays, 
which could explain the inconsistencies which are observed such as the simple difference in 
calibration of standard curves.     
 
  Immunoassay 
 
1.3.1.  Theory of competitive immunoassay design using time-resolved fluorescence 
 
Immunoassays use reagents to generate a signal from a sample.  In the immunometric 
design, an antibody is immobilized onto a plastic surface and captures the test analyte from the 
sample, and a different antibody which is labeled, for example with a radioactive isotope, 
specific for another part of the analyte molecule, is used as a basis for signal generation.  The 
labeled component of the immunoassay is called the tracer.  The analyte that the antibody is 
specific for is known as the antigen.  The material that the antibody is irreversibly bound to is the 
solid phase (Wild, 2005).   
For small molecules such as steroids though, a different immunoassay design is needed.  
Only one antibody is used and it is present in a limited quantity.  The other key reagent, the 
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tracer, is the target analyte and is labeled with a suitable signal generation material.  In the case 
of the in-house immunoassay being validated here, this is biotinylated aldosterone.  The 
proportion of tracer that binds to the limited antibody sites is indirectly proportional to the 
concentration of analyte in the sample.  This is known as a competitive immunoassay. 
In competitive assays the labeled antigen binds to the antibody sites unoccupied by the 
sample antigen.  The addition of unlabeled sample antigen in such a system causes a reduction in 
the number of unoccupied binding sites and therefore, a reduction in binding of labeled antigen, 
making the amount of sample analyte indirectly proportional to the signal obtained.  
Immunoassays do not give direct measurements.  They estimate analyte concentration in 
unknown samples by comparison of signal strength from the labeled reagent to that of similarly 
treated standard samples.  Calibration is the process used to assign values to unknown samples 
using a standard. 
Samples of known antigen concentrations are therefore included as standards, or 
calibrators, and a calibration curve drawn of percentage of activity in the bound fraction 
compared to total activity, against the antigen concentration in the standards.  The concentration 
of antigen in unknown samples may then be interpolated from the calibration curve (Figure 4).  
If the percentage bound is measured then the antigen concentration of an unknown solution can 
be estimated.   
  Signal generation system  In the assay system presented here, the biotin-streptavidin- 
Europium3+ system was used in order to  assess the amount of antigen that is bound.  Biotin is a 
small, water-soluble vitamin (MW 244Da) with extremely high affinity for the egg-white protein 
avidin in free solution.   A bacterial source of avidin, streptavidin (MW 60kDa) is generally 
used, though, which does not contain any carbohydrates and has a neutral isoelectric point.  
Those properties make it inert in assay systems so that there is lower non-specific binding and 
greater sensitivity.  The strength and speed of binding between avidin and biotin is used to link 
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molecules together to create signal generation systems.  Each molecule of streptavidin has four 
binding sites for biotin.  Biotin acts as the label used in place of a radioisotope or enzyme, 
binding to streptavidin and consequently labeling the bound fraction with the signal source.  At 
the end of the assay, a conjugate of streptavidin linked to a signal-generating substance, in this 
case Europium3+-coupled streptavidin, is added.  Streptavidin is incorporated into 
macromolecular  complexes containing many chelation sites for europium ions, producing a 
several thousand-fold amplification of each biotin label.  The conjugate and biotin bind together, 
labeling the bound fraction with the signal source.    
Detection system with time-resolved fluorescence Signal detection occurs via the 
principle of time-resolved fluorescence.  Assay detection limits using conventional fluorescent 
tracers are limited by background interference, such as that due to the natural fluorescence from 
various compounds in biochemical samples such as blood serum.  This interference can be 
avoided by using a fluorophore, like with lanthanide chelates, which has a comparatively long 
decay time and there is a time gap between excitation and measurement of the emitted light, ie. 
10-1000µs vs 1-20ns, giving rise to time-resolved fluorescence (Soini and Kojola, 1985).  In the 
case of the immunoassay presented here, streptavidin is labeled with the lanthanide Europium3+.  
After the main assay incubation and separation, the europium ions are dissociated when an 
enhancement reagent is added and form a new, fluorescent complex with the ligand in the 
enhancement solution, a fluorinated β-diketone.  In the DELFIA® (Wallac) system, a fluorometer 
supplies 1000 pulses of light per second each lasting less than 1µs and fluorescence is measured 
between 400 and 800 µs after each pulse (Wild, 2005). 
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                       Figure 4.  Competitive assay dose response curve. 
 
1.3.2.  Purification by reverse phase High Performance Liquid Chromatography (RP-HPLC) 
 
Data published so far on the measurement of aldosterone in salivary samples has, for the 
most part, been achieved by using 3H- or 125I-labelled aldosterone derivatives.   In order to avoid 
the undesirable health and environmental considerations, and to take advantage of the stability 
and specific activity of biotinylated tracers, the more innovative approach of biotinylating the 
steroid aldosterone, such as has previously been applied to cortisol, was chosen.  However, the 
lack of commercially available biotinylated aldosterone required this conjugation step to be 
carried out in-house with a subsequent step to purify the final solution containing the conjugate 
tracer of excess educts still present which could potentially interfere with the specificity and lead 
to increased background noise.  This step was carried out using chromatographic purification by 
the reverse-phase technique. 
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The definition of chromatography stated by Holman et al in 1993 is the separation of a 
mixture of compounds by continuous distribution between two phases moving with respect to 
one another. HPLC separates steroids by their partition coefficients between aqueous and oily 
phases, samples are injected onto a column and eluted by mixtures of organic solvents and water.  
The degree of hydrophilic and hydrophobic interactions within the molecule and hence its 
chemical structure, for example a ketone versus an alcohol, will effect the separation (Holman et 
al., 1993).  The mobile phase used is liquid as opposed to gas, hence its name, and pressure 
drives this mobile phase through the fine particles of the stationary phase of the column.  
Reverse phase high performance liquid chromatography (RP HPLC) is also known as adsorption 
or partition chromatography (Tuomainen, 1997).  It is used to define the state whereby the 
stationary phase in the column is less polar than the mobile phase.  The stationary phase is the 
non-polar solid support material within the column.  Silica particles are the most commonly used 
material for the stationary phase, onto which carbon chains (C1-C18) are chemically bonded 
(Holman et al., 1993).  Octadecylcylsilane (ODS, C18) has a long hydrophobic alkyl chain and is 
most appropriate, and therefore more frequently used, in capturing small molecules and peptides.  
In general, the fewer the carbon atoms on the alkyl chain the shorter the retention time on the 
column  (Tuomainen, 1997).  
The (silica) beads or particles making up the stationary phase are characterized by 
particle size and pore size, with particle sizes ranging between 3 and 50 microns.  Smaller 
particles give higher separation efficiencies.  Particle pore size is measured in angstroms (1 
angstrom Å = 10-10m).  This stationary phase interacts with analytes based on their polarities so 
that they move down the column at a slower or faster rate along with the polar, aqueous, organic 
mobile phase.  The mobile phase is an aqueous medium to which organic solvents, for example 
methanol or acetonitrile, added to lower its polarity, and other modifiers may be added 
(Kazakevich & McNair, 2002).   
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In RP HPLC retention is mostly influenced by polarity so that hydrophobic compounds 
are retained more than hydrophilic.  Additional polar groups (-OH, -NH2, -COOH) reduce 
retention.  The relative polarity of certain compounds and side chains are given in Table 2.  The 
time it takes for a compound to go from the injector through the column and into the detector is 
called the retention time (Rt).  Column length, diameter, packing material all influence retention 
time but it is mostly  influenced by the amount of interaction a compound has with the stationary 
phase.  A compound which is not retarded at all by the stationary phase will move down the 
column at the speed of the mobile phase and produce what is referred to as the solvent front and 
represents the void of the column.  Depending on the composition of the mobile phase, 
compounds interacting least with the stationary phase of the column will elute first and those 
interacting more will elute later (Holman et al., 1993). 
 
Solvent Polarity Chart    
Relative 
Polarity 
Compound 
Formula 
Group Representative Solvent 
Compounds 
R-H Alkanes petroleum, ethers, ligroin, hexanes 
Ar-H Aromatics toluene, benzene 
R-O-R Ethers diethyl ether 
R-X Alkyl halides tetrachloromethane, chloroform 
R-COOR Esters ethyl acetate 
R-CO-R Aldehydes and 
ketones 
acetone, methy ethyl ketone (MEK) 
R-NH2 Amines pyridine, triethylamine 
R-OH Alcohols methanol, ethanol, isopropanol, 
butanol 
R-COHN2 Amides Dimethylformamide 
R-COOH Carboxylic acids ethanoic acid 
Nonpolar 
 
 
 
 
 
 
 
 
 
 
 
 
Polar H-OH Water Water 
 
Table 2.  Solvent polarity chart reproduced from Chemical Technicians‘ Ready Reference Handbook 
Fourth Edition, Gershon Joseph Shugar, Jack T. Ballinger, 1996. 
 
The mobile phase can be either of a uniform composition (isocratic separation) or applied 
through the column as a gradient.  In the case of a gradient separation, increasing concentration 
of the organic modifier will bring about a reduction in the retention of non-polar compounds, 
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since the mobile phase competes more effectively with the hydrophobic surface of the stationary 
phase (Holman et al., 1993) and allows these compounds to elute through the column. 
Detection of steroids after separation by HPLC in the fractions eluted and collected is 
possible through various techniques the most common being ultraviolet  (UV) spectrophotometry 
which is accomplished due to specific UV absorbing chromophores within a steroid’s structure.  
Functional groups responsible for absorbance, for example ketones, vary in wavelength as does 
maximal absorbance between steroids depending on their chemical structure.  For instance, a 
conjugated ene-one in the A ring of corticosteroids absorbs at 240nm while benzene rings of 
oestradiols at 225 and 280nm.  Solvents themselves are assigned cut-off values below which they 
absorb themselves, acetonitrile for example absorbs at 200nm, not interfering therefore when 
using an absorbance detector set to 245nm (Kazakevich & McNair, 2002).   
 
1.4.  Aims 
It was the purpose of this study to develop and clinically validate a non-isotopic immunoassay 
for the determination of levels of the mineralocorticoid hormone aldosterone in saliva, which 
could potentially be applied as a screening method for the detection of PA involved in  endocrine 
hypertension.   
 
¾ Tracer production  
The first goal of the study was to produce a non-isotopic aldosterone tracer according to 
previously established methods of biotinylating steroid hormones (Dressendorfer, 1992), 
purify it using a RP HPLC method, and validate its performance in the immunoassay to 
detect levels of aldosterone in saliva.   
 
¾ Saliva assay 
The assay design is based on the competition reaction principle, chosen due to the small 
molecular weight of the steroid hormone aldosterone, with biotin as the primary probe and 
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incorporating a commercially available streptavidin-Europium3+ chelate as the second step.  
The method works in conjunction with the DELFIA system for time-resolved fluorometric 
end point measurement (TR-FIA).   
 
¾ Validation 
A small sample volume of 100µl is sufficient for each duplicate measurement.  Validation of 
the assay included: to ascertain whether an extraction step would be necessary, to optimize 
conditions of the assay including concentrations of tracer and capture antibodies utilized, and 
to optimize incubation times necessary for optimal binding.   
 
¾ Clinical validation 
The study aimed to validate, in a clinical setting, the salivary aldosterone assay by showing 
that increases seen in levels of plasma aldosterone in response to physiological stimuli, such 
as during a posture test or after stimulation of the HPA axis with ACTH, are also mirrored in 
saliva, making the assay a possible screening tool for discriminating between healthy and 
Primary aldosteronism(PA) patients.     
 
¾ Aldosterone to Cortisol Ratio 
Examination of the salivary aldosterone measurements in combination with salivary cortisol 
from the same sample, taking into account the circadian rhythm of cortisol and autonomous 
hyper-secretion of aldosterone in PA, gave rise to the possibility of using the ratio between 
the two hormones to improve this discrimination and suggest a cut-off which could be used 
for the differential diagnosis of the disease state. 
 
¾ Application to rodent low sample serum/plasma volume 
During the course of setting up the aldosterone-in saliva assay, the opportunity arose to 
obtain an extremely sensitive monoclonal antibody against aldosterone.  This antibody was 
used to show that the sensitivity achievable with such a highly specific monoclonal antibody 
is adequate to measure aldosterone levels in small sample volumes taken from rodents.  The 
assay was used to test animal model studies ongoing in our laboratory. 
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2.  Materials and Methods 
 
2.1.  Experimental    
2.1.1.  Materials  
2.1.1.1.  Reagents 
Acetic acid (glacial) 100% anhydrous (CH3COOH), Merck 100063 (Darmstadt, Germany)  
Albumin Bovine (BSA), Sigma A7906 (Taufkirchen, Germany) 
Aldosterone (C21H28O5), Fluka 05521 (Taufkirchen, Germany)  
Aldosterone 3-CMO (C23H31NO7), Steraloids Inc. Q2010-000 (Newport, USA)  
Acetonitrile (CH3CN), Chromasolv- Sigma 34851 (Taufkirchen, Germany) 
 
Biotinamidocaproyl Hydrazide, Sigma B3770 (Taufkirchen, Germany)  
 
Cyproterone Acetate (C24H29ClO4), Sigma C3412 (Taufkirchen, Germany)  
 
Dexamethasone (C22H29FO5), Sigma D1756 (Taufkirchen, Germany)  
N,N′-Dicyclohexylcarbodiimide (DCC), Fluka 36650 (Taufkirchen, Germany)  
Dichloromethane (CH2Cl2), Merck 106044 (Darmstadt, Germany)  
Diethylenetriaminepentaacetic acid (DTPA), Sigma D6518 (Taufkirchen, Germany)  
N,N-Dimethylformamide (DMF), Sigma D8654 (Taufkirchen, Germany)  
Dimethyl Sulfoxide (DMSO), Sigma D5879 (Taufkirchen, Germany)  
   
Ethanol (C2H5OH), Merck 100983 (Darmstadt, Germany) 
17α-Ethynylestradiol (C20H24O2), Fluka 02463 (Taufkirchen, Germany)  
 
Fludrocortisone acetate (C23H31FO6), Sigma F6127 (Taufkirchen, Germany) 
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Fluorometholone (C22H29FO4), Sigma F9381 (Taufkirchen, Germany)  
 
γ-Globulin Bovine, Sigma G7516 (Taufkirchen, Germany)  
 
1-Hexanesulfonic Acid Sodium, Sigma H9026 (Taufkirchen, Germany)  
Hydrochloric acid (HCl), Merck 9057 (Darmstadt, Germany)  
N-hydroxysuccinimide (NHS), Fluka 56480 (Taufkirchen, Germany) 
 
Methanol (CH3OH), Merck 106018 (Darmstadt, Germany) 
Medroxyprogesterone 17-acetate (C24H34O4), Sigma M1629 (Taufkirchen, Germany)  
 
Norethisterone acetate (C22H28O3), Aldrich R182265 (Taufkirchen, Germany) 
d(-)-Norgestrel (C21H28O2), Sigma N2260 (Taufkirchen, Germany)  
 
Phosphate Buffered Saline tablets (PBS), Sigma P-4417 (Taufkirchen, Germany)  
ortho-Phosphoric acid (H3PO4), Merck 100573 (Darmstadt, Germany)  
Prednisolone (C21H28O5), Sigma P6004 (Taufkirchen, Germany)  
2-Propanol (C3H8O), Sigma-Chromasolv 34863 (Taufkirchen, Germany) 
Polyethyleneglycol 10000 (HO(C2H4O)nH), Merck 817008 (Darmstadt, Germany)  
Potassium carbonate (K2CO3), Merck 104928 (Darmstadt, Germany) 
Potassium hydrogen phthalate (C8H5KO4), Merck 104874 (Darmstadt, Germany)  
 
Sodium azide (NaN3), Merck 6688 (Darmstadt, Germany)  
Sodium chloride (NaCl), Merck 6404 (Darmstadt, Germany)   
di-Sodium hydrogen phosphate anhydrous (Na2HPO4), Merck 106586 (Darmstadt, Germany)  
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Sodium hydrogen carbonate (NaHCO3), Merck 106329 (Darmstadt, Germany)  
Sodium phosphate dibasic dihydrate (Na2HPO4 x 2H2O), Fluka 71638 (Taufkirchen, Germany)   
Spironolactone (C24H32O4S), Sigma S3378 (Taufkirchen, Germany)  
Streptavidin-Europium, Perkin-Elmer Life Sciences (Turku, Finland) 
 
2-Thenoyltrifluoroacetone (C8H5F3O2S), Sigma T27006 (Taufkirchen, Germany) 
Tri-octylphosphinoxid (C24H51OP), Merck 8254 (Darmstadt, Germany)   
Triton X-100, Sigma T8787 (Taufkirchen, Germany)  
Trizma base (Tris-(hydroxymethyl)-aminomethane), Sigma T1503 (Taufkirchen, Germany)  
Tween 20, Sigma P1379 (Taufkirchen, Germany)  
Tween 40, Sigma P1504 (Taufkirchen, Germany)  
 
Water for chromatography (H2O), Merck 115333 (Darmstadt, Germany)  
 
2.1.1.2.  Antibodies 
Anti-aldosterone polyclonal (rabbit) antibody, Acris Antibodies GmbH Catalog No. BP 233,  
 (Hiddenhausen, Germany). 
Anti-rabbit (goat) Immunoglobulins, 1H7 in-house O.D. 1.728 (1.23mg/ml) 
Anti-mouse (rabbit) Immunoglobulins, DAKO Code No. Z 0109 (Hamburg, Germany) 
Anti-aldosterone monoclonal mouse antibody, A2E11, IgG1 kappa  
The cell culture supernatant was kindly provided by C.E. Gomez-Sanchez, Division of 
Endocrinology, G.V. Montgomery VA Medical Center and University of Mississippi 
Medical Center, Jackson, Mississippi, USA.)  
 
2.1.1.3. Buffers 
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Primary antibody Coating Buffer 
For 1 litre of buffer: 8.9g Sodium phosphate dibasic dihydrate (Na2HPO4 x 2H2O) was dissolved 
in 800ml of distilled water and the pH set to 7.4 using Phosphoric acid (H3PO4).  The volume is 
then brought up to 1 liter with distilled water.  The buffer was stored at room temperature for 1 
month. 
Secondary (Capture) antibody Coating Buffer (See Assay Buffer) 
 
Assay Buffer for Immunoassay (LKC) 
For 5 litres of buffer: 45.0g of sodium chloride (NaCl), 30.0g of Tris-(hydroxymethyl)-
aminomethane, 2.5g of sodium azide (NaN3), and 0.5g of Tween 40 were dissolved in 3litres of 
deionised water.  Subsequently, the pH was adjusted to 7.75 using concentrated hydrochloric 
acid (HCl).  25.0g of Bovine Serum Albumin (BSA), 2.5g Bovine γ-Globulin, and 39.35mg 
Diethylenetriaminepentaacetic acid (DTPA) were then added and the volume was brought up to 
5litres.  The assay buffer was left overnight to fully dissolve and was then filtered first over a 8µ 
filter (Fa.Sartorius 11301-50-N) and subsequently over a 0.8µ filter (Fa.Sartorius 11304-50-N).  
The buffer was stored at 4°C for up to 3 months. 
 
Wash Buffer for Immunoassay 
For 2 litres of wash buffer: 10 Phosphate Buffered Saline tablets were dissolved in deionised 
water along with 1ml of Tween 20.  The buffer was stored at room temperature for up to one 
week.   
Enhancement Solution 
Stock solution A 
5.55g 2-Thenoyltrifluoroacetone (C8H5F3O2S) and 966.5mg Tri-octylphosphinoxid (C24H51OP) 
were dissolved in 5ml of absolute ethanol.  50ml of Triton X-100 was added and brought up to 
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250ml with Aqua ad injectabilia water.  This stock solution was stored in the dark at 4°C for up 
to 6 months. 
 
Stock solution B 
3.46g of Potassium hydrogen phthalate (C8H5KO4) was dissolved in 15ml of Acetic acid 
(CH3COOH) and taken up to 250ml with Aqua ad injectabilia water, pH set to 3.15.  This stock 
solution was stored in the dark at 4°C for up to 3 months. 
Working solution 
2.5ml of Stock solution A and 25ml of Stock solution B were mixed and taken up to 250ml with 
Aqua ad injectabilia water.  This solution was stored at room temperature for up to 3 months. 
 
Artificial Saliva 
Stock solution 
For a 10x concentrate: 4.2g sodium hydrogen carbonate (NaHCO3), 0.5g sodium chloride 
(NaCl), and 0.2g potassium carbonate (K2CO3) were added to 100ml distilled water.  The buffer 
was stored at 4°C for up to 6 months. 
Working solution 
The stock solution was further diluted at 1:10 with distilled water.  Stored at 4°C, always made 
fresh on the day of use. 
 
Elution Buffers for Chromatography column 
50mM Tris-HCl Buffer (Buffer A) 
3.028g  Tris-(hydroxymethyl)-aminomethane dissolved in 400ml distilled water.  The pH was 
adjusted to 7.8 using Hydrochloric acid (HCl) and subsequently taken up to 500ml with distilled 
water. 
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86% Methanol/H2O Buffer (Buffer B Knauer column) 
 430ml methanol (CH3OH) were taken up to 500ml with chromatography gradient water. 
86% Acetonitrile/ H2O Buffer (Buffer B Phenomenex column) 
 430ml acetonitrile (CH3CN) were taken up to 500ml with chromatography gradient water. 
 
Dichloromethane Extraction Buffer 
50mg Polyethyleneglycol 10000 (HO(C2H4O)nH) in 500ml Dichloromethane (CH2Cl2). 
 
2.1.2.  Equipment 
Automatic microtiter plate multi washer, TECAN, SLT Labinstruments (Crailsheim,  
Germany) 
Victor3, Perkin Elmer (Wiesbaden, Germany) 
Jouan GR 422 Centrifuge, Thermo Fischer Scientific, (Germany) 
ÄKTA™ purifier UPC-900, Amersham Biosciences Europe GmbH, (Freiburg, Germany) 
 
Synergi 4u Fusion-RP 80Å reverse phase chromatography column, Phenomenex Inc.,  
(Aschaffenburg, Germany) 
Vertex-Säule Eurospher 100 C18 5µm,  Knauer Advanced Scientific Instruments, (Berlin, 
Germany) 
DU®-62 Spectrophotometer, Beckman Coulter GmbH, (Krefeld, Germany) 
 
2.1.3.  Miscellaneous materials 
Maxisorp-microtiter plates (Nunc, Roskilde, Denmark, No. 442404) 
pH meter (Wissenschaftlich-Technische Werkstätten, Weilheim, Germany) 
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2.2.  Clinical Studies 
2.2.1.  Materials 
NaCl isotonic solution 0.9%, Braun, (Melsungen, Germany) 
Disinfectant spray, Cutasept® FBode Chemie (Hamburg, Germany) 
250µg synthetic human ACTH 1-24 (Synacthen; Novartis) 
 
2.2.2.  Equipment 
Salivette® Sarstedt, No. 51.1534 (Nümbrecht, Germany) 
Venous access: VenflonPro 18 Gauge, Becton Dickinson, (Heidelberg, Germany) 
Multidirectional Discofix® stopcocker for infusion therapy, Braun, (Melsungen, Germany) 
Cannula Fixation Dressing, Curapor® i.V. Lohmann Rauscher, (Regensdorf, Germany)  
BD Discardit™ II 2ml and 10ml Syringes, Becton Dickinson, (Heidelberg, Germany) 
Elastic bandage, Nobafix®, (Wetter, Germany) 
Multi-Adapter for S-Monovette, Sarstedt, (Nümbrecht, Germany) 
Combi-Stopper, closing cone combi blue, Braun, (Melsungen, Germany) 
I.V. administration set for gravity infusion Intrafix® Air, Braun, (Melsungen, Germany)  
S-Monovette Blood Collection System, Sarstedt 2,6ml (Serum) and 7,5ml (Plasma EDTA)  
Sarstedt, (Nümbrecht, Germany) 
Mandrin, Becton Dickinson, (Heidelberg, Germany) 
RR-machines 
Powder-free examination gloves, Sempercare® Semperit Technische Produkte  
Ges.m.b.H & Ko KG, (Vienna, Austria) 
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2.3.  Methods - Experimental 
2.3.1.  Synthesis of aldosterone 3-CMO-biotin conjugate tracer 
Commercially available derivatives of aldosterone and biotin were coupled as described 
previously in Dressendörfer et al., 1992, for the synthesis of the aldosterone3-CMO-biotin 
conjugate, over three consecutive days.  On day 1, preparation of aldosterone 3-CMO active 
ester derivative was as follows: 5mg (11.5µmol) of aldosterone3-CMO (Steraloids Inc., 
Newport, USA) was dissolved in 100µl of dry, amine-free N,N-Dimethylformamide (DMF) 
(Sigma).  5.6mg (50µmol) N-hydroxysuccinimide (NHS) (Fluka) and 10.3mg (50µmol) N,N′-
Dicyclohexylcarbodiimide (DCC), (Fluka) were dissolved in 40µl and 60µl of  DMF 
respectively, and added to the aldosterone 3-CMO.  The reaction mixture was stored at room 
temperature under light-exclusion for 24hours.  On day 2, coupling of aldosterone-NHS ester to 
biotin was as follows: 9.3mg (25µmol) Biotinamidocaproyl Hydrazide, (Sigma) was dissolved in 
100µl of Dimethyl Sulfoxide (DMSO), (Sigma).  The completely dissolved biotin was then 
added to the initial reaction mixture and left at room temperature for another 24hours under 
light-exclusion.  On day 3, the final volume (300µl) of the reaction mixture was further diluted at 
1:10 with a 50mM Tris-HCl buffer (pH 7.8), to a final concentration of 1.6 mg/ml, aliquoted and 
stored at -20°C.  
 
2.3.2. Reverse phase chromatographic purification of the aldosterone tracer 
The aldosterone 3-CMO-biotin conjugate (1.6 mg/ml), was further diluted with 50mM Tris-HCl 
buffer to a concentration of 0.1 mg/ml and 120µl aliquots, corresponding to 0.012mg, were 
injected into the column.  The aldosterone conjugate was applied to two reverse phase 
chromatography columns, the “Vertex-Säule Eurospher 100 C18 5µm” provided by Knauer 
Advanced Scientific Instruments and the “Synergi 4u Fusion-RP 80A, 250 x 4.6mm” from 
Phenomenex.   
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2.3.2.1.  Vertex-Säule Eurospher 100 C18 5µm”- Knauer Advanced Scientific Instruments 
The elution buffer used to run the column was a linear gradient of 0 - 100% Buffer B (86% 
Methanol/H2O) starting with 100% Buffer A (50mM Tris-HCl pH 7.8).  The elution was run at a 
flow rate of 0.7ml/min in 20 column volumes (Figure 5 and 6).   
 
2.3.2.2.  Synergi 4u Fusion-RP 80A, 250 x 4.6mm - Phenomenex Ltd. 
Two different elution systems were used to purify the conjugate using the Phenomenex  column.  
In the first instance, the elution buffer used to run the column was also a linear gradient as 
described above, of 0 - 100% Buffer B (86% Acetonitrile/H2O) starting with 100% Buffer A 
(50mM Tris-HCl pH 7.8).  The elution was run at a flow rate of 0.7ml/min with a gradient length 
of 20 column volumes (Figure 7).  In the second instance, an isocratic gradient of 33% Tris-HCl/ 
67% Acetonitrile-H2O(86-14%) buffer was run, with a step to 100% Acetonitrile-H2O(86-14%) 
buffer after 60 minutes, run at 0.7ml/min, also in 20 column volumes (Figure 8).   
 
For both columns and in all runs, a volume of 100µl was injected into the column via the 
injection loop, corresponding to 0.01mg of the biotinylated aldosterone conjugate.  The 
wavelength on the absorbance detector was set to 254nm and fractions of 500µl were collected.  
There was a set column pressure of 9.8 MPa.  At the end of each run the columns were washed 
through with 5 column volumes of the final running elution, i.e. 86% Methanol/H2O for the 
Knauer column and 86% Acetonitrile/H2O for the Phenomenex column.   
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2.3.3.  Evaluation of  fractions 
2.3.3.1.  Aldosterone content with RIA MAIA Adaltis  
 
Highest absorbance(mAU) peak fractions at 254nm were diluted in Assay Buffer at 1:1000, so 
that values would fall within the measurable range of the assay, and added as samples for 
analysis of aldosterone content using a commercially available radio-immunoassay (Aldosterone 
MAIA, Adaltis Italia S.p.A.), see Table 4.  Peak fractions that corresponded to two fractions 
were pooled and measured together. A selection of baseline fractions were also added for 
measurement to ascertain that there was minimal or no aldosterone within these fractions. 
 
2.3.3.2.  Fractions as assay tracer 
As a preliminary protocol the anti-aldosterone capture antibody was diluted at a 1:1000 and the 
incubation time was set to 1.5hours.  In subsequent assays, the concentrations of capture 
antibody and incubation time were modified in order to optimize the assay procedure 
accordingly.  The concentration range of the calibrators used in the assays to test activity of the 
tracer fractions, incubation times and concentration of antibodies was initially reported in the 
ng/ml range for reasons of simplicity and clarity in the graphic representation.  Calculations and 
ED50 values are reported in pg/ml.  Once the assay range was established, for example in Figures 
13, 14, and 15, the x-axis of the standard curve is presented in the pg/ml range. 
 
As an initial screening step, the fractions found to have highest aldosterone content were added, 
at different dilutions, and used as tracer in the assay in order to assess overall maximum counts, 
displacement capability, and to assess whether this correlated to concentration of aldosterone 
obtained from the radioimmunoassay.  Fractions not showing peaks were also assessed to ensure 
that biotinylated aldosterone was present.  Only a selection of the fractions tested are shown in 
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graphic representation in the ‘Results’ section, although several more were tested in order to 
ascertain the optimum tracer for use in the immunoassay. 
 
Peak fractions 93, 95 and 97 from the linear gradient Knauer Run 1  were tested at dilutions of 
1:10, 1:100, 1:1000, and 1:10000 as tracer in the assay (ex. Fraction 97, Figure 5).  Peak 
fractions 92/93, 94/5, and 96/97 from linear gradient Knauer Run 2  were tested at dilutions of 
1:100, 1:1000, 1:5000 fraction 94/95, and 1:10000 respectively (ex. Fraction 96/97, Figure 6).  
Fractions 68/69, 70 (Figure 7) and 64/65, 81/82 (not shown), Phenomenex Run 1 were tested at 
1:1000.  Peak fractions 67, 68 and 69, from Phenomenex Run 2, as well as pooled fractions 
63/64, 65/66, 72 and 73 were tested likewise, as were fractions 25, 29, 30/31, and 34 and 50, 
pooled 51/52 and 55 from isocratic Phenomenex Run 3 were all used at 1:1000.  Similarly, 
fractions 34, 35/36, 37, 38, 39, 40, 50/51, 90/91 from isocratic Phenomenex Run 4 were also run 
at a 1:1000 dilution to ascertain activity (ex. Fractions 39, 40, 50/51 and 90/91, Figure 8). 
 
2.3.3.3.  Direct comparison of activity at equal concentration 
A previously established suitable tracer concentration for the cortisol in saliva assay described in 
Dressendoerfer et al 1992, was found to be 20pg/well.  For this reason, after initial screening, the 
fractions were each diluted accordingly to correspond to a final concentration of 20pg/well in 
order to acquire a direct comparison of binding activity (Figure 9, Table 5).  Furthermore, this 
step was carried out in order to find the fraction with a combination of highest aldosterone 
content and lowest amount of excess biotin, that is, the most purified fraction giving least 
amount of background producing non-specific binding. 
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2.3.3.4.  Optimising concentration  of chosen tracer fraction 
For competitive assays the rate of change of signal upon addition of sample hormone or of 
labelled antigen tracer, is greatest when a small amount of antigen tracer is added as this limits 
the “signal-to-noise-ratio”.  For this reason it is optimum to have the lowest amount of tracer 
possible so that small changes in sample antigen can be detected, as the rate of change is more 
visible.  Two tracer fractions from Knauer Run 1 and from isocratic Phenomenex 4, (Figure 10) 
were used at 2 and 20 pg/well with varying antibody concentrations and incubation time.  
Fraction 40 from Phenomenex run 4 was also tested at 2pg, 5pg and 20pg per well (Figure 11). 
 
2.3.4.  Conditions of the assay  
2.3.4.1.  Optimisation of incubation time between tracer and standards 
Fraction 40 from the isocratic elution run on the Phenomenex column (2.19µg/ml) was used as 
tracer at a concentration of 2pg/well to look at the effect of an extended incubation time between 
the tracer and the standards.  Assay times of 1.5 hours, overnight, and 48 hour incubations were 
compared, and total counts, total displacement and ED50’s were assessed (Table 6).  A 
combination of an overnight incubation with the Knauer fractions 97, and 96/97 and 
Phenomenex fractions 51/52 and 40 at 2 and 20pg/well, again with the capture antibody at 
1:1000 (Figure 12) was applied to determine optimum concentration of the tracer at the longer 
established incubation time of an overnight duration. 
 
2.3.4.2.  Optimising concentration of polyclonal anti-aldosterone capture antibody  
For similar reasons which concentration of tracer needs to be at lowest concentrations possible, 
the antibody concentration also needs to be as low as possible in order to minimise errors in 
estimating the unoccupied sites.  The displacement capability of the tracer Phenomenex fraction 
40 at 2pg/well and an overnight incubation, was evaluated at higher, 1:5000, and lower, 1:100, 
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titration of the polyclonal Acris capture antibody (Table 7).  Total counts, total displacement and 
ED50’s were assessed. 
 
2.3.4.2.  Optimising concentration of monoclonal anti-aldosterone capture antibody 
The concentration of the monoclonal A2E11 capture antibody was optimised by coating at 
increasing dilutions from 1:2500 to 1:50000 and the total counts, displacement and ED50’s were 
assessed (Figure 13, Table 8).  The tracer Phenomenex fraction 40 was at 2pg/well with an 
overnight incubation time.  
 
2.3.5.  Working dilution of antibodies  
Direct coating of the capture antibody to the solid phase, i.e. the microtitre plate well, can result 
in conformational changes that reduce its affinity for the analyte.  To avoid this problem a 
‘primary’ antibody is coated first, containing immunoglobulins against the corresponding species 
in which the antibody is raised.  This antibody, which is specific for the Fc, constant, region of 
the capture antibody, allows for correct orientation, leaving the antigen-specific Fv region 
available for binding.  This will then allow for highest binding capacity of the immobilized 
antibody and for good reproducibility of coating conditions. 
 
2.3.5.1.  Primary coating goat-anti-rabbit immunoglobulins  
A goat anti-rabbit immunoglobulin (IgG) antibody, produced in-house, (1H7), was immobilised 
onto Maxisorp-microtiter plates (Nunc, Roskilde, Denmark) at a concentration of 300ng per 
200µl well in 50mM sodium phosphate (Na2HPO4 x2H2O) pH 7.4 coating buffer and left for a 
minimum of one overnight incubation.   
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2.3.5.2.  Primary coating  rabbit anti-mouse immunoglobulins  
A rabbit anti-mouse IgG antibody (DAKO, Hamburg, Germany) was immobilised onto 
Maxisorp-microtiter plates (Nunc, Roskilde, Denmark) at a concentration of 300ng per 200µl 
well in 50mM sodium phosphate (Na2HPO4 x 2H2O) pH 7.4 coating buffer and left for a 
minimum of one overnight incubation.   
 
2.3.5.3.  Secondary coating - polyclonal rabbit anti-aldosterone (Acris Antibodies GmbH) 
Goat-anti-rabbit IgG coated plates were washed 3 times and subsequently commercially 
available rabbit anti-aldosterone capture antibody (Acris, Hiddenhausen, Germany) was used at a 
1:1000 dilution in Assay Buffer, i.e. 100ng/well, was pipetted into each well and left for at least 
one overnight incubation.  Plates could be stored for up to one month without loss of activity.   
 
2.3.5.4.  Secondary coating - monoclonal mouse anti-aldosterone antibody (A2E11) 
Rabbit anti-mouse IgG antibody coated plates were washed 3 times and subsequently mouse 
anti-aldosterone antibody (A2E11) was used at a 1:10000 dilution in Assay Buffer was pipetted 
into each well and left for at least one overnight incubation.  Plates could be stored for up to two 
weeks without loss of activity.   
 
2.3.6.  Preparation of aldosterone calibrators  
A stock solution of aldosterone (Fluka, Taufkirchen Germany) was reconstituted in pure ethanol 
to 10mg/ml and stored at -80°C.  This was consequently serially diluted with artificial saliva, 
prepared according to the German Industry Norm (DIN 53 160) standards, to 10000pg/ml to give 
the highest calibrator and further to give 5000, 2000, 1000, 500, 200, 100, 50, 20, 10 and 5pg/ml.  
The calibrators were kept at -20°C for several months. 
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2.3.7.  Final Assay Procedure 
Microtitre plates were coated with a combination of either the goat anti-rabbit immunoglobulin 
(IgG) antibody produced in-house and subsequently the polyclonal rabbit anti-aldosterone 
capture antibody (Acris, Hiddenhausen, Germany), or the rabbit anti-mouse IgG antibody 
(DAKO, Hamburg, Germany) and subsequently the mouse anti-aldosterone monoclonal capture 
antibody (A2E11).  Previous to the assay procedure, plates were washed three times in an 
automatic microtiter plate washer (TECAN, SLT; Crailsheim, Germany) using an in-house 
prepared 0.05% PBS/Tween-20 buffer and subsequently 50 µl of each sample were pipetted in 
duplicate, directly onto the plates along with aldosterone calibrators and controls.  Subsequently, 
100 µl of biotinylated aldosterone tracer were pipetted into each well, diluted in assay buffer at 5 
pg/well, the plate was sealed with self-adherent foil to avoid evaporation and incubation 
proceeded for an hour at room temperature on a horizontal microtiter plate shaker (TECAN, SLT 
Labinstruments, Crailsheim, Germany) before being left overnight at 4°C.   
The following day, the incubation was terminated by washing three times on the automatic 
microtiter plate washer.  200 µl per well of a Streptavidin coupled to Europium conjugate 
(PerkinElmer/Wallac, Turku, Finland) were then added and incubated for thirty minutes on the 
horizontal shaker at room temperature.  After a 6-fold wash of the plate, an in-house 
„enhancement solution“ was added and incubated on the shaker for fifteen minutes, used to 
transfer the Europium conjugate into a fluorescent complex.  Amount of biotinylated aldosterone 
bound was then measured using a fluorometer (VICTOR3, PerkinElmer). 
 
2.3.8.  Extraction of aldosterone from saliva and plasma/serum 
For the extraction of aldosterone from saliva samples, 200µl of each saliva sample were vortexed 
at a low speed with 2ml of dichloromethane (DCM)/Polyethylene glycol (PEG) 10000 for 30 
minutes.  For the extraction of aldosterone from human plasma samples, 200µl of plasma were 
 57
vortexed with DCM as for saliva.  For the extraction of aldosterone from rodent plasma or serum 
samples where a volume of 200µl was not available, 50µl were used instead.   
When the two phases were separated, the organic phase (1.7ml) was removed, transferred to 
another tube and left to evaporate to dryness overnight.  The following day, the sample was 
reconstituted with 10µl methanol and 160µl DIN artificial saliva.  Duplicate samples of 50µl 
were then directly pipetted onto the microtiter plate.  In the case of the smaller volume of serum 
or plasma samples used for rodent aldosterone level analysis, the concentration (pg/ml)  given by 
the assay was multiplied 4-fold in order to compensate for the dilution factor after reconstituting 
the sample.   
 
2.3.9.  Saliva sampling 
The sampling device used to collect saliva was the Sarstedt salivette, containing a 40 x 9mm 
cellulose tampon (see Appendix 7.3).  The salivette is held at the rim of the suspended insert so 
that the stopper is removed.  The swab is removed from the salivette and gently chewed for 2 
minutes, or kept in the mouth until the patient or participant could no longer prevent 
himself/herself from swallowing the saliva produced. Participants were asked not chew the 
salivette for 30 minutes after eating or drinking, immediately after taking any kind of oral 
medication or tablets, immediately after smoking, or immediately after brushing teeth to avoid 
contamination from blood and to ensure there was no contamination of saliva with interfering 
substances.  The saturated swab was then returned to the suspended insert and the salivette is 
closed firmly with the stopper.  Time and date of collection, as well as name or code were 
labeled on each tube.  Before analysis, the sample was thawed and centrifuged so the saliva was 
transferred to the outer tube, the inner tube and swab were discarded.  Saliva was pipetted 
directly from the outer tube after the inner tube was discarded. 
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2.3.10.  Assay Validation 
2.3.10.1.  Cross –reactivity 
Assay specificity is the ability of an antibody to produce a measurable response only for the 
analyte of interest and cross-reactivity is a measurement of antibody response to substances other 
than the analyte.  A pure sample of the cross-reacting substance is spiked into an analyte-free 
matrix to give a suitably wide range of concentrations.  Cross-reactivity is defined at the point 
where the reduction in signal corresponds to 50% of the signal achieved in the absence of analyte 
(B/Bo of 50%, ie ED50), as a percentage of the analyte concentration giving the same fall in 
signal (Wild, 2005). 
% cross-reactivity  =       concentration of analyte giving 50% B/Bo___ 
  concentration of cross-reactant giving 50% B/Bo 
 
Polyclonal Rabbit anti-aldosterone (Acris) 
A series of both endogenously found and synthetic steroids were tested for potential cross-
reactivity with the anti-aldosterone capture antibody.  These steroids were added as samples in 
the assay in increasing concentrations and standard displacement curves were obtained.  
Comparison of the ED50 values allowed us to acquire the % cross-reactivity (Table 9).  
 
A2E11 monoclonal anti-aldosterone antibody 
The monoclonal antibody against aldosterone used in the immunoassay was prepared and cross-
reactivities were tested as previously described in Gomez et al 1987.  Briefly, three different 
tracers and separation procedures were used, namely, ammonium sulphate separation and 
charcoal adsorption with tritium label, and charcoal separation with [125I]iodohistamine-
aldosterone tracer (Table 10).   
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2.3.10.2.  Sensitivity – Lower limit of detection 
Sensitivity can be defined as the concentration at which one can be certain that  a sample is not 
zero.  There are two ways sensitivity can be evaluated, analytical and functional.  Analytical 
sensitivity is determined most commonly by repeatedly assaying the zero standard and defining 
the limit of sensitivity as being the concentration corresponding to two or three standard 
deviations above the mean.  This equates to the probability that a single replicate of sample is not 
part of the distribution of the zero analyte values (Wild, 2005).   
Polyclonal Rabbit (Acris) and A2E11 monoclonal anti-aldosterone  
The analytical sensitivity or lower limit of detection (LOD) of the assay, was determined by 
assessing the zero standard in a typical assay a total of 30 times and the mean (± standard 
deviation; SD) value of the counts was calculated.  A statistically significant difference from the 
zero standard was taken to be more than 2 times the standard deviation from this repeated mean.  
This corresponding aldosterone value was thereafter determined from its intercept with the 
displacement curve (polyclonal Acris antibody Figure 14, A2E11 monoclonal antibody Figure 
15). 
 
2.3.10.3.  Linearity 
Linearity is an additional check of the accuracy of the assay and is used to judge whether or not 
dilutions of a sample lie parallel to the calibration curve.  Often called dilution experiments, this 
experiment answers the question “if a sample is diluted will it give the same result or not”.  
Assessed by assaying samples diluted in an analyte-free matrix (Wild, 2005). 
 
Polyclonal Rabbit anti-aldosterone (Acris) 
Four samples of pooled saliva were spiked with pure aldosterone (ethanol stock of 10mg/ml), 
previously diluted in artificial saliva to a concentration of 1000pg/ml, and measured.  The 
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‘spiked’ pools were then serially diluted again with artificial saliva and the values obtained upon 
measurement with the assay were compared to the expected calculated concentration (Table 11). 
 
A2E11 monoclonal anti-aldosterone antibody 
A plasma sample which was measured above the highest standard point of the linear range of the 
assay was diluted (1:2) in the matrix medium used to produce the calibrators and measured.  This 
sample was then further serially diluted (1:4, 1:8, 1:16, 1:32) and the average recovery rate was 
determined (Table 12).   
 
2.3.10.4.  Recovery 
Recovery is the test most commonly used to demonstrate the accuracy of an assay.  Accurate 
quantities of analyte are added to samples and the incremental increase in concentration is 
determined.  It assesses the calibration of the assay and the influence of differences between 
sample and calibrator matrices (Wild, 2005). 
 % recovery  =      measured increase in concentration_ x 100% 
       predicted increase in concentration 
 
Polyclonal Rabbit anti-aldosterone (Acris) 
A saliva sample, which was measured for an initial aldosterone concentration, was serially 
diluted at 1:2 with each of the 9 standards and the mean % recovery was calculated (Table 13). 
A2E11 monoclonal anti-aldosterone antibody 
A plasma sample, measured for initial aldosterone concentration, was extracted and reconstituted 
a total of nine times and the sample was then pooled.  Each of the standard points was then added 
at a 1:1 dilution to an aliquot of the sample.  Average recovery for each sample was found at 
102% (Table 14). 
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2.3.10.5.  Precision (Reproducibility) 
Precision describes the repeatability of an analytical technique and is an estimate of the error in 
the technique, expressed as the coefficient of variation (%CV) at a particular analyte level, and 
occurs due to combined effects of antibody characteristics, separation, detection, and 
manipulation errors.  Within-run precision of a sample is determined when the same sample is 
run on several occasions within the same assay.  Twenty replicates of sample are included spaced 
equidistantly throughout the assay.  Between-run precision is an index of the ability of the assay 
to reproduce the same result on the same sample from run to run and from day to day.  %CV was 
determined by the standard deviation of the mean / mean x100 (Wild, 2005). 
 
Polyclonal Rabbit anti-aldosterone (Acris) 
The intra-assay coefficients of variation were determined after a 10-fold measurement of pooled 
saliva samples of known aldosterone high, intermediate and low concentrations, also before and 
after extraction (Tables 15). The inter-assay coefficients of variation were calculated by a 20-fold 
measurement of pooled saliva samples of known aldosterone high, intermediate and low 
concentrations and were determined respectively (Table 16).   
A2E11 monoclonal anti-aldosterone antibody 
Intra-assay coefficients of variation were determined by 20-fold measurements of pooled plasma 
samples with high, intermediate and low aldosterone concentrations which were extracted, 
reconstituted, pooled  again and then added as samples on the same plate (Table 17).  Inter-assay 
coefficients of variation were determined by 20-fold measurements, on consecutive days, of 
plasma samples extracted and reconstituted on each occasion (Table 18).  Inter-assay coefficients 
of variation were also determined for three pools of non-extracted saliva samples with low, 
intermediate and high aldosterone concentrations (Table 19). 
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2.3.11.  Salivary aldosterone determination with and without salivette 
In order to determine whether or not levels of aldosterone are affected in any way by using the 
salivette device, such as by the interference or cross-reaction of substances which may be present 
in the tampon insert, ten pairs of samples collected using the Sarstedt salivette and collected by 
spiting directly into the external tube of the salivette, were measured using the Acris assay.  
Samples were frozen at -20°C once and then thawed and centrifuged before pipetting onto the 
plate.  Participants were asked to abide by sampling guidelines prior to collection.  No 
stimulation of salivary flow rate was applied for collection without the salivette.   
 
2.3.12.  Pre-analytical storage stability of salivettes 
As a test of storage stability, five healthy volunteers were asked to provide four consecutive 
saliva samples within a few minutes. One of the samples was immediately centrifuged, mixed 
thoroughly and subsequently aliquoted (200µl) and stored at 4°C as well as room temperature for 
up to 7 days (see Figure 16, ‘standard’).  After 1, 3, and 7 days at the same conditions the other 
samples were also frozen, thawed and then centrifuged before finally being analyzed for 
aldosterone content on the same day and in the same run. 
 
2.3.13.  Correlation of calibrators with commercially available RIA 
A set of aldosterone calibrators prepared in-house (0 to 2000pg/ml) were added, without any 
prior treatment, as samples and measured with the DPC Biermann (Coat-A-Count) 
radioimmunoassay (Figure 17, Table 20).  Similarly, a set of DPC calibrators  taken directly 
from the kit were added as samples and measured in the in-house TRFIA using the Acris 
polyclonal antibody before and after extraction using dichloromethane/PEG (Figure 18, Table 
21).  These same calibrators were also measured using the A2E11 assay after extraction (Figure 
19, Table 22 ).  
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2.3.14.  Extraction of saliva and plasma – ‘Acris assay’ 
2.3.14.1.  Salivary aldosterone  
A series of 188 saliva samples were measured using the Acris assay before and after extraction 
using dichloromethane/PEG 10000.  Samples were thawed and extracted on the day previous to 
the assay and an extra aliquot was kept in an eppendorf cup for the following day for the ‘no 
extraction sample’ in order to avoid repeat freeze thawing of the original sample.  Two examples 
of day profiles from healthy participants as well as a morning to mid-afternoon profile from a 
patient suspected of Primary aldosteronism (Figure 20a, b, c, d) are shown.     
 
2.3.14.2.  Plasma aldosterone 
A series of plasma samples were tested for aldosterone content using the DPC RIA and 
correlated to the results obtained by the Acris assay.  200µl from each of the samples underwent 
extraction and reconstitution, with the standard protocol described above, for measurement in the 
Acris assay.  Plasma samples collected from two healthy participants, one taking part in a 
posture test study which was carried out in the clinic, to show that steep increases may still be 
monitored after extraction, and another collecting a normal day profile, are shown in Figure 21, 
correlation between the two assays Figure 22.  A set of samples was also further evaluated using 
a decreased volume of 100µl.  Extraction and reconstitution were carried out according to the 
procedure above and aldosterone values acquired upon completion of the assay were multiplied 
by a factor of 2 to compensate for the dilution factor.  These samples were measured alongside a 
standard 200µl extraction and compared to this and the DPC assessment (Figures 23a and b, 24a 
and b). 
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2.3.15.  Extraction of plasma – ‘A2E11 assay’ 
The A2E11 antibody was used to determine whether or not plasma aldosterone concentrations 
may be measured in smaller volumes than the 200µl and 100µl already established.  Initially, a 
set of plasma samples selected from a healthy subject carrying out a day profile collection were 
assessed by the standard extraction method to determine if plasma aldosterone measurement is in 
fact possible using the A2E11 antibody.  Following to this, a smaller volume of 50µl was used 
while all the following steps of the procedure remained unchanged, and a factor of 4 was added 
to the end results after measurement of the plate (Figure 25a, b, and c). 
 
2.4.  Methods - Clinical   
 
Samples included for salivary and plasma aldosterone, as well as salivary cortisol measurements 
were obtained from PA patients admitted to the Ludwig Maximilians University Clinic, and from 
randomly chosen healthy volunteers. Salivary samples were also obtained from nine PA patients 
admitted to the Hospital Europeen Pompidou in Paris, France.  Samples collected from patients 
and volunteers taking part in the ACTH stimulation test were obtained from an ongoing study 
concurrently taking place at the clinic.  For all studies involving the collection of human 
samples, approval of the study protocol was obtained by the Medical Faculty of the University of 
Munich Ethical Committee (Project Nr. 069/04).  Written informed consent was obtained from 
all patients and healthy volunteers participating in all studies and consent forms, questionnaires 
and description of the study were handed out to each individual beforehand (see Appendix 7.1 
and 7.2).  Where PA patients admitted to the LMU Clinic participated, confirmation of the 
disease was by failure to suppress aldosterone to less than 80pg/ml in the saline infusion test.   
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2.4.1.  Clinical validation of salivary aldosterone 
2.4.1.1  Acris assay  clinical validation – Day profile study 
It was the purpose of this study to obtain simultaneous saliva and plasma samples from healthy 
participants throughout the course of the day in order to show that the pattern according to 
diurnal rhythms which is seen in plasma aldosterone can also be monitored in saliva.  Nine 
healthy participants (4 men and 5 women) were recruited from the staff of the clinic as well as 
from random volunteers (mean ± (SD), aged men: 35 ± 9.35, women: 24 ± 2.4, BMI men: 23.7 ± 
2.0, women: 20.6 ±1.2, Table 23).  These participants were on no medication apart from thyroxin 
or the contraceptive pill and did not report any endocrine disorders.  At 08:00 an indwelling 
catheter was inserted into the antecubital vein and serum and saliva samples were obtained 
simultaneously every two hours thereafter up to and including 18:00.  During this time 
individuals were allowed to go about normal daily activities.  Figure 26 shows the mean (± 
SEM) results for salivary and plasma aldosterone.   
 
2.4.1.2.  Mean aldosterone levels in PA and healthy participants 
Salivary sample collection for the accumulation of total salivary aldosterone comparisons 
between PA and healthy volunteers (Figure 27) as well as for separate day profiles from PA and 
healthy (Figures 28 and 29 respectively) was as described in the section above ‘Salivary 
sampling’.  For the determination of a total salivary aldosterone and plasma correlation (Figure 
30), plasma and saliva samples from single as well as day profiling studies were used.  For single 
time point samples and day profiles, plasma samples were collected as described above ‘Day 
Profile Study’ by an indwelling catheter inserted into the antecubital vein.  Plasma samples were 
assayed for aldosterone content by the DPC Biermann RIA.   
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2.4.1.3.  Posture test study 
A cohort of 31 healthy, normotensive, volunteers with no medical history of renal failure or 
hypertension were recruited (15 male, 16 female, age ranged from 18 to 30 years, BMI ± (SD) 
22.2 ± 1.8).  Sixteen of the volunteers had a history of regular cigarette consumption. These 
participants smoked an average of 12.2 cigarettes per day (range, 4 to 30) and smoked for an 
average of 7 years (range, 1 to 15).  The volunteers were on no medication excluding thyroxin or 
the contraceptive pill.  Demographics for the participants are shown in Table 3.  
 
Male Female 
 
Smokers Non-smokers Smokers Non-smokers 
n 7 8 8 8 
Age 25 ± 2.4 23.4 ± 3.2 21.6 ± 2.8 21.6 ± 3.1 
BMI 24.1 ± 1.3 22.2 ± 1.4 21.8 ± 1.9 20.9 ± 1.3 
OC - - 6/8 5/8 
RR Syst BL 128.7 ± 10.6 123.3 ± 12.7 120.9 ± 7.8 115.4 ± 10.5 
RR Syst Std 122.9 ± 12.5 130.0 ± 19.3 118.5 ± 7.8 110.5 ± 16.4 
RR Diast BL 81.0 ± 8.5 69.3 ± 8.0 74.9 ± 7.5 64.0 ± 8.9 
RR Diast Std 77.6 ± 11.2 80.9 ± 7.6 69.6 ± 6.7 67.4 ± 10.7 
 
Table 3.  Posture study demographics. Data are shown as mean  ± SD 
n, No. of  participants, OC, Oral Contraceptive, Syst BL and Diast BL, systolic and diastolic  blood 
pressures at baseline, Syst Std and Diast Std, systolic and diastolic bloop pressures after standing. 
 
Study design and sample collection 
The study was approved by this institution’s local ethics committee.  Subjects were asked to give 
written informed consent.  The participants were asked to come in to the hospital in a fasting 
state at 08:00 and were given a standard breakfast provided by the clinic.  An indwelling catheter 
was inserted into a forearm vein and subsequently participants were asked to assume the supine 
position before the first simultaneous plasma and saliva samples were taken at 10:00.  This was 
designated as time point t0.  Samples were collected every 15 minutes for one hour until 11:00 
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and then one hour later at 12:00.  This was the last supine sampling time point, t120, after which 
the subjects rose to a standing position.  Samples were then collected again at 15 minute intervals 
for the next hour, and subsequently at the next two hour time points, t240 and t300 respectively. 
During the last two hours of the study the participants were allowed to leave the hospital and 
return for subsequent collections.  Blood pressure was measured manually from the other arm 
after the first supine hour as well during the first hour after standing. 
 
Hormone assays 
Blood samples collected were used for the measurement of plasma aldosterone (Coat-a-Count, 
Diagnostic Products Corporation Biermann GmbH, Bad Nauheim Germany), and salivary 
aldosterone was measured using the Acris assay.  Salivary aldosterone responses before and after 
change in posture were compared to the plasma aldosterone at each time point (Figure 31) and 
overall data was analysed for differences found between males and females and differences 
related to smoking status (Figures 32 and 33 respectively). 
 
2.4.1.4.  ACTH stimulation test 
Saliva samples were collected along with plasma sampling carried out during an ACTH 
stimulation test, as part of an ongoing study taking place at the clinic, looking at the response of 
patients with suspected Conn’s syndrome to various stimuli.  Twenty participants, 12 Conn’s 
syndrome patients (6 men and 6 women, aged 57 ± 11.5) and 8 healthy volunteers (2 men and 6 
women, aged 26 ± 2.9) were studied for basal and post-ACTH aldosterone levels in plasma and 
saliva.  Baseline salivary and plasma samples were collected an hour before participants were 
given 250µg synthetic human ACTH 1-24 (Synacthen; Novartis) as a baseline measurement and 
subsequently simultaneous saliva and plasma samples were taken at 15 minutes after injection 
and then every 15 minutes following that (Figure 34). 
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2.4.1.5.  Aldosterone to Cortisol Ratio  
Saliva samples were collected from a total of 68 subjects who participated in the study.  27 of 
whom were confirmed with PA in the form of aldosterone producing adenoma (APA) or bilateral 
adrenal hyperplasia (BAH), and 41 healthy volunteers (control).  PA patients were aged 14 to 82 
years, 16 were female and 21 male, and had a mean (± SEM) BMI of 25.4 ± 1.03. Control 
participants were aged between 19 and 65 years, 12 were female and 33 male, and they had a 
mean BMI of 23.4 ± 0.5.  Concentrations of salivary aldosterone were analyzed by the Acris in-
house TRFIA and salivary cortisol by a commercial luminescence competitive immunoassay 
(Cortisol Luminescence Immunoassay, IBL; Hamburg, Germany) and the ratio between the two 
hormones was thereby determined,  aldosterone to cortisol ratio (ACR).  Daytime saliva samples, 
taken between 7 and 12am, and evening samples between 6 and 10pm, were collected using 
Sarstedt salivettes. Furthermore, in a subgroup of 10 PA and 8 Control subjects an ACTH 
stimulation test was performed to investigate the influence of stimulation of the pituitary adrenal 
axis on the ACR (Figure 36). ACRs in saliva found in the morning were compared to those in the 
evening in order to establish the ratio which could be set as a cut-off and used to discriminate 
between PA patients and healthy subjects.  Furthermore, comparison of the ACR determined 
using morning samples to that given in the evening was used to demonstrate the most appropriate 
time of day for carrying out sampling (Summary Table 24, Figures 35-37). 
 
2.4.1.6.  ‘A2E11 assay’ clinical validation in saliva 
For the clinical validation of the A2E11 assay in saliva two sets of day profile samples collected 
from patients with PA at half-hour intervals were measured using the assay according to the 
standard procedure described above, ‘Final Assay Procedure’ without pre-treatment of the 
samples with DCM/PEG extraction.  Samples were also evaluated using the Acris in-house assay 
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according to the same procedure and using the same set of calibrators so that a comparison could 
be made between aldosterone levels given by the two assays (Figures 38). 
 
2.4.2.  Clinical validation in rodent serum/plasma using the A2E11 assay 
The studies presented here were conducted in accordance with institutional guidelines for the 
humane treatment of animals using mice from the indicated strains.  All animals were housed in 
a room lighted 12hours per day at an ambient temperature.  Animals were allowed 1week to 
recover after arrival and had free access to rodent diet and tap water ad libitum until the initiation 
of the experiment.   
 
2.4.2.1.  Basal aldosterone in male and female wild type mice  
All mice serum samples used for the validation of the aldosterone assay in small volumes of 
rodent serum or plasma were obtained from the Institute of Molecular Animal Breeding and 
Biotechnology, LMU.  Mice were kept under standard (specified pathogen-free, SPF) conditions 
and had free access to rodent diet (V1534; ssniff, Soest, Germany) and tap water ad libitum.  
Serum samples were stored at -20°C in eppendorf tubes until the time of assessment.   
In order to determine mean, baseline serum aldosterone concentrations in male and female wild 
type mice, serum samples from 75 mice (C57BL/6 x NMRI) aged between 3 and 11 weeks, were 
assessed using the A2E11 assay according to the standard procedure incorporating a 50µl 
volume (as described in the section above “Extraction of plasma – A2E11 assay”), and results 
were separated according to gender differences (Figure 39).  Aldosterone concentrations were 
subsequently analyzed according to mice of different ages (at 3, 5, 7, 9 and 11 weeks) in order to 
determine differences occurring during development (Figure 40, Table 25).  Statistical 
significances between the different age groups of mean male and female mice values shown in 
Table 26. 
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2.4.2.2.  Suppression and stimulation of the HPA axis in mice   
Serum samples were collected from twenty-one mice which were tested for stimulation with 
ACTH, dexamethasone suppression and a control group for comparison to baseline values.  
Seven mice (aged 11 weeks) were injected intraperitoneally (i.p.) for 10 consecutive days with a 
daily dose of 250 µl ACTH solution (Synacthen ®, Novartis Germany, 0.25 mg/ml). A second 
group (n = 7) received daily i.p. injections of 200 µl Dexamethasone solution (Vetoquinol, 
Firma, Germany; 4 mg/ml).  A control group (n = 7) received 250 µl vehicle only per day (0.9 % 
v/v NaCl; B. Braun, Melsungen, Germany) i.p.  On day 10, 3 hours after the last injection, mice 
were sacrificed and blood samples were collected in the afternoon.  As above, serum samples 
were stored at -20°C in eppendorf tubes and were assessed using the A2E11 assay according to 
the standard procedure using 50µl (Figure 41).  
 
2.4.2.3.  Effect of an increased potassium diet on the adrenal RAAS  
Mice serum samples used for the assessment of aldosterone levels in mice given a high or low 
potassium containing diet were collected from the Institut für Molekulare Medizin und 
Zellforschung, Universität, Freiburg.  Twenty-six, 12 week-old male wild type mice (CD1), were 
divided into 3 groups and were fed for 5 weeks with a low potassium chow diet and distilled 
water in the low potassium group(n = 9), regular chow and distilled water in the control group (n 
= 10), and high potassium chow (141mg/kg Na+, 11381mg/kg K+, 179 mg/kg Cl-) and distilled 
water containing 2% v/v KCl in the high potassium group (n = 7).  Mice were anaesthetized 
using isoflurane before decapitation and subsequently trunk blood was collected and serum 
samples were transferred in aliquots to 1.5ml Eppendorf tubes containing 10µl 0.5M EDTA.  
Blood was spun down at 5000rpm for 10minutes at 4°C, and the supernatant (serum) was 
transferred to new 1.5ml Eppendorfs. Samples were stored at -20°C until the time of assessment.  
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Samples were measured using the A2E11 assay with a 50µl sample (Figure 42a), as well as the 
DPC RIA (Figure 42b). 
 
2.5.  Statistical analysis 
For reasons of clarity in figures and text means ± SEM or ± SD are provided,  as indicated.  No 
assumptions were made about the probability distribution of the data sets and therefore non- 
parametric methods were applied.  Comparison of two paired groups was carried out using the 
Wilcoxon signed-rank test, independent samples and comparison of two unpaired groups was 
tested using the Mann-Whitney U test, comparison of three or more unmatched groups was done 
by Kruskal-Wallis, and Spearmann rank correlations were used to quantify the association 
between two variables.  Only results with P< 0.05 were considered statistically significant.  
 
3. Results 
 
For the chromatographic separation of the biotinylated aldosterone 3-CMO conjugate (1.6 
mg/ml) from excess biotin and other educts which could potentially still be present in the final 
reaction solution we utilized two Reverse Phase HPLC columns and applied two different 
gradient systems in order to optimize the separation. 
 
3.1.  Reverse phase chromatographic purification of the aldosterone 3-CMO-biotin conjugate 
3.1.1.  Vertex-Säule Eurospher - Knauer Advanced Scientific Instruments 
Chromatogram Knauer column - Run 1 (Figure 5): Fraction peaks collected and tested were 
peaks 93, 95, and 97, the highest peak fractions occurring between 70 and 80 minutes.  Knauer 
column - Run 2 (Figure 6): Fraction peaks collected and tested were peaks 92/93, 94/95, and 
95/96, the highest peak fractions occurring between 75 and 85 minutes.  Fractions corresponding  
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Figure 5. Run 1 using the Knauer column with a linear gradient solvent change. 
Fraction 97 
Fraction 96/97 
Figure 6. Run 2 using the Knauer column with a linear gradient solvent change. 
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to smaller peaks and to baseline fractions were also tested for both Knauer runs in order to 
ascertain if aldosterone is still present, or present in higher concentrations than that found in the 
highest peaks.  Most other peaks observed in the chromatogram occurred previous to the three 
major ones seen at around 80 minutes.  These smaller peaks contain more polar compounds that 
were eluted first from the column and are likely to correspond to other educts in the solution 
such as the excess biotin or the aldosterone ester created on day 1. 
 
3.1.2.  Synergi 4u Fusion-RP - Phenomenex  
The two linear gradient runs using the Phenomenex column were carried out first (ex. Run 1, 
Figure 7).  Both of these yielded two major peaks at around 50 and 35 minutes,  peaks 68/69 and 
70 in the first, and 67, 68, and 69 in the second.  Two isocratic gradient runs were  also carried 
out following to this (ex. Run 4, Figure 8).  Major peaks were found at around 35 and 30 minutes 
respectively.  For Run 3 these were peak fractions 47, 48/49, and 51/52, and for Run 4 fractions 
35/36, 37, and 40.  As with the Knauer column, most other peaks observed in the chromatogram 
occurred previous to these highest absorbance peaks and were assumed also to correspond to 
educts or possibly impurities present in the solution or the eluent buffers.  Minor peaks and 
baseline fractions were again tested for aldosterone content.    
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3.2.  Evaluation of  Fractions 
3.2.1.  Aldosterone content with RIA MAIA Adaltis 
The MAIA assay showed that peak fractions 97 and 94/95, 96/97 from Knauer Run 1 and 2 
respectively, and peak fractions 68, 69 from Phenomenex Run 2, 48/49 and 51/52, Phenomenex 
Figure 7. Run 1 using the Phenomenex column with a linear gradient solvent change. Fractions at 1:1000. 
Fraction 70 
Fraction 40    
Fraction 50/51  
Fraction 90/91
Figure 8. Run 4 using the Phenomenex column with an isocratic gradient solvent change.  Fractions at 1:1000. 
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Run 3, and 40 from Phenomenex Run 4, had the highest aldosterone content (Table 4).  After 
dilution to obtain values within the working range of the assay, concentrations were extrapolated 
to the ‘true value’ and found to range from 13 to 2190 ng/ml.  Smaller peaks from all the runs 
that were tested did not exceed 2000 pg/ml in each case, some baseline fractions contained 
between 300 and 1200 pg/ml.  Though some were tested for confirmation of a negative result, 
most of these fractions were not tested further in assay runs due to the, at least thousand-fold, 
difference in aldosterone content. 
Summary of chromatography runs – fractions with highest Aldo content 
RP Column Chromatography Gradient Fraction MAIA 
pg/ml 
Max 
counts 
at 
1:1000 
pg/ 
well 
at 
1:1000 
Knauer Linear;  0 - 100% B Peak 93 12700 280325 1.3 
Run 1  50mM Tris pH 7.8a - 86% MeOHb Peak 95 154700 102074 15.5 
  Peak 97 200000 82299 20.0 
Knauer Linear;  0 – 100% B Peak 92/93 85400 296145 8.5 
Run 2 50mM Tris pH 7.8 a - 86% MeOHb Peak 94/95 325000 392651 32.5 
  Peak 96/97 1253000 181214 125.3 
Phenomenex Linear;  0 – 100% B Peak 68/69 36300 105901 3.6 
Run 1 50mM Tris pH 7.8 a - 86% ACNc Peak 70 15300 35786 1.5 
Phenomenex Linear;  0 – 100% B Peak 67 145000 312060 14.5 
Run 2 50mM Tris pH 7.8 a – 86% ACNc Peak 68 1579000 368214 158.0 
  Peak 69 1920000 314306 192.0 
Phenomenex Isocratic with step to 100% B Peak 47 14710 253403 1.5 
Run 3 33% (Tris pH 7.8 a - 86% ACNc) Peak 48/49 948000 363062 94.8 
  Peak 51/52 1431000 115483 143.1 
Phenomenex Isocratic with step to 100% B Peak 35/36 187000 296122 18.7 
Run 4 33% (Tris pH 7.8 a - 86% ACNc) Peak 37 1255000 347389 125.5 
  Peak 40 2190000 110442 219.0 
 
Table 4.  Aldosterone content and maximum counts of each fraction at a 1:1000 titration used as tracer in 
the immunoassay.   a Buffer A for both linear and isocratic runs, 50mM Tris HCl at pH 7.8, b Buffer B for 
linear gradient runs, 86% Methanol/H2O, c Buffer B for isocratic gradient runs 86% Acetonitrile/H2O. 
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3.2.2.  Fractions as assay tracer 
To determine if the aldosterone present in the chosen fractions was coupled to biotin and 
functions as a tracer and to see if the displacement activity correlates with concentration of 
aldosterone given in the MAIA, fractions were added at several dilutions as tracer.  Comparison 
of displacement curves obtained upon completion of the assay, showed that concentration of 
aldosterone present in the fraction did not always correlate to the maximum counts seen in the 
assay, possibly due to too much biotin still present in the fraction which produces extra 
background counts.   
 
However, the displacement curves also showed that the aldosterone present in the highest peak 
fractions was in fact biotinylated and functions as tracer to displace aldosterone present in 
standards, with higher or lower sensitivity.  Displacement was assessed by the B/Bmax 
relationship, corresponding to binding activity compared to total binding.  Since a higher dilution 
than 1:1000, ie 1:10000, did not increase sensitivity of the tracer and decreased the total counts 
to lower than adequate this was not repeated for the Phenomenex run fractions.  Knauer Run 1 
fraction 97, Run 2 fraction 96/97, Phenomenex Run 1 fraction 70, Run 3 fraction 51/52, and Run 
4 fraction 40 revealed the highest displacement down to 0.1 of maximum binding, Bmax. 
Several smaller peaks and baseline fractions which were chosen randomly and added as tracer 
confirmed that they did not contain biotinylated aldosterone but a substance which was not in 
competition with the aldosterone in the standards and gave little or no displacement. 
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3.2.3.  Direct comparison of activity at equal concentration 
At 1:1000 the concentration of the tracer corresponded to different amounts for each fraction, 
some above and some below 100pg/well.  For this reason it was necessary to have a direct 
comparison of all the fractions at the same concentration in order to find the fraction containing 
highest counts overall with the lowest background, non-specific binding.  All fractions were 
therefore diluted to 20pg/well and total counts and maximum displacement were compared 
(Figure 9, Table 5).  
 
Knauer fraction 97 and 96/97, from Runs 1 and 2, showed a high displacement but overall low 
counts at 20 pg/well.  Other fractions, such as Knauer 94/95 and Phenomenex 48/49 for example, 
which had a high aldosterone content and high counts showed a poor displacement of only 12% 
and 20% respectively.  Isocratic Phenomenex run fractions 51/52 and 40 had a high displacement 
of 54% and 46% which, though slightly lower than Knauer fraction 96/97, had total counts 
which were almost twice as high.  Fractions 51/52 and 40 were more sensitive than other 
fractions, for example 68 and 69 from the linear gradient runs which displaced only 22% and 
13% of the aldosterone present in the standards. 
Figure 9.  Direct comparison of all Knauer and Phenomenex fractions at 20pg/well. 
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Displacement capability of tracer at equal concentrations 
RP Column Fraction pg/well Max counts 
Maximum % 
displacement 
Knauer Peak 93 20 197895 7 
 Peak 95 20 105298 32 
 Peak 97 20 61034 41 
Knauer Peak 92/93 20 188174 0 
 Peak 94/95 20 214736 12 
 Peak 96/97 20 57231 57 
Phenomenex Peak 68/69 20 143960 20 
 Peak 70 20 72028 31 
Phenomenex Peak 67 20 224937 21 
 Peak 68 20 185193 22 
 Peak 69 20 118572 13 
Phenomenex Peak 47 20 291280 14 
 Peak 48/49 20 228024 20 
 Peak 51/52 20 90170 54 
Phenomenex Peak 35/36 20 259688 15 
 Peak 37 20 225081 18 
 Peak 40 20 111807 46 
 
Table 5.  Comparison of total counts and total displacement when fractions are added as tracer in the 
immunoassay at an equal concentration of 20pg/well.   
 
 
3.2.4.  Conditions of the assay  
3.2.4.1.  Optimisation of tracer concentration and incubation time between tracer and standards 
A combination of extended incubation times with the tracer at 20 pg and a lower, 2pg, per well 
concentration was assessed using the fractions with highest sensitivity, Knauer fractions 97 and 
96/97, and Phenomenex fractions 51/52 and 40 (Figures 10-12).   
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Figures 10.  48hour incubation of tracer fractions.          Figure 11. Overnight incubation and decreasing                
                                                                                           concentration of aldosterone tracer. 
Figure 12.  Overnight incubation of Knauer and Phenomenex fractions, Acris at 1:1000 
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Assay incubations times of 1.5 hours, overnight, and 48 hours were compared (Table 6).  An 
overnight incubation compared to 1.5 hours significantly increased total counts by 20000.  
Although increasing the incubation time further, to 48 hours, did increase the displacement 
potency of the tracer by a small amount, this was not considered enough to justify the increased 
total assay time for practical reasons.  From the same set of assays it became apparent that 
decreasing the concentration of the tracer from 20pg to 2pg/well  increased the sensitivity of the 
tracer and increased total displacement from 67% to 75%, though there was an overall drop in 
counts of 22000, which could be compensated for by increasing the incubation time. 
 
Effect of increasing incubation time 
 Max counts ED50 (pg/ml) 
Maximum % 
displacement 
1.5 hours 14000 321 81.3 
Overnight 37000 505 81.5 
48 hours 38000 379 88.7 
 
Table 6. Displacement capability of tracer (Phenomenex fraction 40) at 2pg/well and Acris at 1:1000, 
with increasing incubation times. 
 
 
3.2.4.2.  Optimising final concentration of polyclonal capture antibody and tracer.  
Comparison of an increased concentration of the Acris antibody from 1:1000 to 1:100 showed 
that total counts did not increase overall, with the added disadvantage that the ED50 also 
increased from 200pg/ml to 470pg/ml.  Total counts decreased drastically to 13000 upon further 
dilution of the capture antibody down to 1:5000, with a concurrent decrease in the total 
displacement.  Data is summarised in Table 7. 
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Effect of varying concentration of capture Ab 
 Max counts ED50 (pg/ml) 
Maximum  % 
displacement 
1:100 21500 465 85.4 
1:1000 22000 201 86.9 
1:5000 13000 149 76.9 
 
Table 7. Displacement capability of tracer (Phenomenex fraction 40) at 2pg/well and an overnight 
incubation, at a higher, 1:5000, and lower, 1:100, titration of the Acris capture antibody. 
 
Following this set of experiments it was decided to utilize Phenomenex fraction 40, as opposed 
to fraction 51/52 or Knauer fraction 97, although it had equal displacement capability, because 
fraction 40 had a higher concentration of aldosterone and could be used at a lower dilution.  
Therefore, further dilution of the capture antibody was combined with increasing concentrations 
of tracer fraction 40 to 5 and 10 pg/well to see if this would increase its sensitivity.  Increased 
counts of 43000 and 56000 were seen at 5 and 10 pg/well respectively.  At 5 pg/well ED50’s 
were almost identical at 255 and 273 pg/ml, whereas there was a significant increase when the 
tracer was used at 10 pg/well to 390.  The fact that at 5 pg/well the tracer showed practically the 
same displacement capability as at 2 pg/well but had significantly higher counts, meant that it 
was chosen as the optimum tracer concentration (Figure 11). 
 
3.2.4.3. Optimising final concentration of monoclonal capture antibody 
The monoclonal anti-aldosterone, A2E11, antibody was tested at a series of dilutions in order to 
determine the optimum concentration producing highest counts and highest displacement 
capability of the tracer used in the final assay procedure (Figure 13a and b, Table 8).  Maximum 
displacement was reached only after a 1:10000 dilution but then remained the same up to 
1:30000.  Further diluting the antibody up to 1:50000 decreased the ED50 although not 
significantly and furthermore, this occurred at the expense of the decreasing counts and a 
decreased total displacement. 
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  A2E11 with primary coating anti-mouse IgG 
Dilution factor Max Counts 
ED 50 
(pg/ml) 
Maximum % 
displacement 
1:2500 139593 494 94.4 
1:5000 134772 212 96.8 
1:10000 119566 88 97.4 
1:20000 66119 58 97.4 
1:30000 46646 55 97.4 
1:40000 35266 61 94.9 
1:50000 34386 46 95.8 
 
Table 8.  Optimisation of concentration of coating monoclonal capture antibody A2E11.  Tracer used was 
Phenomenex fraction 40 at 2pg/well and an overnight incubation. 
 
 
 
 
 
Figure 13a and b.  Monoclonal antibody A2E11 at increased dilutions with Phenomenex fraction 40 at 5pg/well. 
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3.3.  Assay validation 
3.3.1.  Cross-reactivities 
3.3.1.1.  Polyclonal rabbit anti-aldosterone (Acris) 
Minimal cross-reactivity was found overall, also for substances present in high concentrations in 
the plasma such as cortisol (Table 9).  The highest cross-reactivity, 0.01%, was found in the 
closest chemically related steroid, 18-OH Corticosterone.  Cross-reactivity was also low for 
synthetic steroids, with the highest occurring in prednisolone, 0.009%.  The aldosterone receptor 
antagonist spironolactone had a displacing potency of 0.002%. 
 
Endogenous Steroids % Cross-reactivity Synthetic Steroids % Cross-reactivity 
Androstendione 0.003 Cyproterone Acetate 0.002 
Corticosterone 0.006 Dexamethasone 0.001 
18-OH-Corticosterone 0.01 Ethinyloestradiol ND 
Cortisol 0.004 Fludrocortisone Acetate 0.003 
Deoxycorticosterone 0.003 Fluorometholone ND 
Deoxycortisol 0.001 Medroxyprogesterone 0.002 
DHEA NDa Norethisterone Acetate 0.003 
Estradiol ND Norgestrel ND 
Estrone ND Prednisolone 0.009 
Pregnenolone ND Spironolactone 0.002 
17-OH-Pregnenolone ND   
Progesterone 0.005   
17-OH-Progesterone 0.001   
Testosterone 0.002   
NDa - not detectable 
 
Table 9.  Cross-reactivity – Acris antibody 
 
3.3.1.2.  Monoclonal anti-aldosterone antibody (A2E11) 
The monoclonal antibody against aldosterone used in the immunoassay was prepared as 
previously described (Gomez-Sanchez et al., 1987).  Cross-reactivities for cortisol and 
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corticosterone were found by those authors to be at <0.003% and were at <0.3% for other 
potentially cross-reacting steroids (Table 10).  Highest % cross-reactivity was for the aldosterone 
metabolite tetrahydroaldosterone, found at 2.78%, 3.15%, and 5.0% with each of the RIA tracer 
separation methods but fortunately this is a metabolite which does not occur in saliva. 
 
% Cross reactivity by tracer and separation method 
Endogenous Steroid 3H ASa 3H Chb 125I Chc 
3α,5β - THaldosterone 2.78 3.15 5.0 
18-Oxocortisol 0.083 0.1 0.1 
Cortisol <0.0025 <0.003 <0.003 
Corticosterone <0.0025 <0.003 <0.003 
DOC <0.0025 <0.003 <0.003 
Progesterone <0.0025 <0.003 <0.003 
18-OH- DOC 0.065 0.07 0.27 
18-OH-Corticosterone 0.089 0.12 0.1 
18-OH-Cortisol <0.0025 <0.003 <0.003 
Cortisone <0.0025 <0.003 <0.003 
 
Table 10.  Cross-reactivity – A2E11 antibody (table reproduced from Gomez et al 1987) 
atritium label, ammonium sulphate separation;  btritium label, charcoal separation; ciodinated     
 aldosterone-3-CMO-histamine, charcoal separation. 
 
3.3.2.  Sensitivity  
3.3.2.1.  Polyclonal rabbit anti-aldosterone (Acris)  
The zero standard was measured in a typical assay a total of 30 times and the mean (± standard 
deviation; SD) value of the counts was calculated (39996 ± 1063).  A statistically significant 
difference from the zero standard was taken to be more than 2 times the standard deviation from  
this repeated mean (ie. 39996 – 2128 = 37868 counts).  This value was thereafter determined 
from its intercept with the displacement curve and found to correspond to 19pg/ml for a 50µl 
sample (Figure 14).   
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3.3.2.2.  Monoclonal anti-aldosterone antibody (A2E11) 
The zero standard was again measured in a typical assay a total of 20 times and the mean (±SD) 
value of the counts was calculated (50791 ± 3444).  More than 2 times the standard deviation 
from this repeated mean (i.e. 43903 counts) was thereafter determined from its intercept with the 
displacement curve to correspond to 8 pg/ml (Figure 15).  
 
 
Figure 14.  Sensitivity – Limit of detection for the Acris antibody assay. 
 
Figure 15.  Sensitivity – Limit of Detection for the A2E11 antibody assay. 
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3.3.3.  Linearity 
3.3.3.1.  Polyclonal rabbit anti-aldosterone (Acris) 
Four samples of pooled saliva were spiked with pure aldosterone previously diluted in artificial 
saliva to a concentration of 1000pg/ml, and measured at 1355, 1815, 1628, and 1496pg/ml.  
After serial dilution of the ‘spiked’ pools with artificial saliva the values obtained upon 
measurement with the assay were compared to the expected calculated concentration (Table 11) 
and a mean recovery of 106.3% was found, showing that there is good linearity of diluted 
samples.   
 
3.3.3.2. Monoclonal anti-aldosterone antibody (A2E11) 
Measurement of a plasma sample after a 1:2 dilution in the matrix medium used to produce the 
calibrators yielded a concentration of  963 pg/ml.  After further serial dilutions (1:4, 1:8, 1:16, 
1:32) this sample had an average recovery rate of 105% (Table 12).   
 
 
 
 
 
 
 
 
Table 12.  Linearity A2E11 assay - plasma sample serially diluted in the “0” standard after extraction. 
 
 
 
 
 
 
 
 
 
 
Dilution 
factor 
Measured 
value Expected value 
(%) Expected 
value 
original 
sample >std -- -- 
1:2 963 -- 100 
1:4 509 481.5 106 
1:8 272 240.8 113 
1:16 125 120.4 104 
Dilution  
in  
0 std 
1:32 62 60.2 103 
Avg % expected    105 
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Table 11. Linearity – Acris Antibody. Saliva sample serially diluted in the “0” standard after extraction. 
 
 
 Dilution Factor 
Measured 
value 
Calculated 
value 
% Expected 
value 
Spiked Pool A __ 1355 __ 100 
 1:2 655 678 96.8 
 1:4 332 339 98.1 
 1:8 156 169 92.3 
 1:16 94 85 111 
 1:32 51 42 121.5 
Mean %    104 
Spiked Pool B __ 1815 __ 100 
 1:2 874 908 96.4 
 1:4 521 454 114.9 
 1:8 247 227 109 
 1:16 120 113 106.3 
 1:32 73 57 129.3 
Mean %    111 
Spiked Pool C __ 1628 __ 100 
 1:2 774 814 95.1 
 1:4 362 407 88.8 
 1:8 219 204 107.8 
 1:16 112 102 109.8 
 1:32 67 51 132 
Mean %    107 
Spiked Pool D __ 1496 __ 100 
 1:2 695 748 92.9 
 1:4 368 374 98.4 
 1:8 195 187 104.2 
 1:16 104 94 110.9 
 1:32 51 47 109.9 
Mean %    103 
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3.3.4.  Recovery 
3.3.4.1.  Polyclonal rabbit anti-aldosterone (Acris) 
A saliva sample with an average concentration, after four consecutive measurements, of 
443pg/ml, was diluted at 1:1, with each of the standards 0 to 2000pg/ml and the mean recovery 
was 100.9% (Table 13). 
Table 13. Recovery – Acris antibody.  Each of the aldosterone standards were added to a saliva sample, 
which was previously spiked to 444 pg/ml, at a 1:1 ratio. 
 
 
3.3.4.2.  Monoclonal anti-aldosterone antibody (A2E11) 
Two plasma samples, measured at 29 pg/ml and 20 pg/ml, were each extracted and reconstituted 
a total of nine times and each of the standard points was then added at a 1:2 dilution to the 
sample.  Average recovery for each sample was found at 102% and 113% (Table 14). 
 
 
 
 
 Aldosterone added (pg/ml) 
Measured 
value 
Calculated 
value 
% Expected 
value 
Spiked Pool  _ 444 _ 100 
 0 222 221.8 100.2 
 10 237 226.8 104.6 
 20 230 231.8 99.4 
 50 277 246.8 112.4 
 100 289 271.8 106.1 
 200 317 321.8 98.4 
 500 445 471.8 94.3 
 1000 668 721.8 92.6 
 2000 1219 1221.8 99.7 
Avg % expected    101 
 89
 
1:1 Dilution 
with std (pg/ml) 
Measured 
value 
Expected 
value 
% Expected 
value 
Sample A 29 -- 100 
+ 5 20 17 117.6 
+ 10 20 19.5 104.1 
+ 20 27 24.5 108.6 
+ 50 46 39.5 115.4 
+ 100 65 64.5 100.3 
+ 200 119 114.5 103.5 
+ 500 239 264.5 90.4 
+ 1000 476 614.5 77.5 
+ 2000 1053 1014.5 103.8 
Avg % expected   102 
 
Table 14. Recovery – A2E11 antibody.  Recovery of samples after extraction and spiked at a 1:1 dilution 
with each of the standard points. 
 
 
 
 
3.3.5.  Precision 
3.3.5.1.  Polyclonal rabbit anti-aldosterone (Acris) 
The intra-assay coefficients of variation after a 10-fold determination for aldosterone 
concentrations of low sample pools 69 and 47, intermediate samples 124 and 94, and high 
samples 215 and 210pg/ml before and after extraction respectively, were 14.2 and 13.8, 10.1 and 
9.7, and 7.2 and 6.0% respectively (Table 15).  The inter-assay coefficients of variation were 
calculated by a 20-fold measurement of pooled saliva samples with aldosterone concentrations of 
31, 33, 92, 94, 254 and 189 pg/ml and were determined at 35.1, 15.7, 16.3, 9.0, 14.2 and 8.7% 
respectively (Table 16).   
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 no 
extraction 
after 
extraction 
 no 
extraction 
after 
extraction 
 no 
extraction 
after 
extraction
204 205 125 93 82 56 
205 198 134 82 77 46 
200 213 134 85 69 51 
243 195 117 89 61 56 
228 229 104 87 78 40 
222 225 127 105 70 37 
228 208 108 100 56 48 
215 217 116 90 67 48 
210 218 145 97 54 50 
High 
Samples 
Pool 1 
193 193 
Intrmd 
Samples 
Pool 1 
127 110 
Low 
Samples 
Pool 1 
79 40 
Mean 214.8 210.0  123.6 93.7  69.4 47.3 
std dev 15.5 12.5  12.5 9.1  9.8 6.5 
%CV 7.2 6.0  10.1 9.7  14.2 13.8 
Table 15.  Within-assay CV for Acris; validation before and after extraction of saliva samples with 
DCM/PEG (duplicate values). 
 
 
 
High 
Samples 
Pool 1 
Intmd 
Samples 
Pool 1 
Low 
Samples 
Pool 1 
 253 80 29 
 219 89 29 
 284 97 43 
 277 94 33 
 247 104 31 
 229 94 36 
 266 105 36 
 266 97 38 
 228 82 31 
 247 95 35 
mean 251.4 93.5 32.5 
std dev 21.9 8.4 5.1 
%CV 8.7 9.0 15.7 
 
Table 16.  Between-assay CV for Acris antibody assay.  Saliva samples without extraction (duplicate 
values). 
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3.3.5.2.  Monoclonal anti-aldosterone antibody (A2E11) 
Intra-assay coefficients of variation were determined by 20-fold measurements of pooled plasma 
samples with aldosterone concentrations of 18 pg/ml, 34 pg/ml, and 139 pg/ml which were 
extracted, reconstituted, pooled  again and then added as samples on the same plate and found to 
be 7.3%, 6.3%, and 4.4%, respectively (Table 17).  Inter-assay coefficients of variation were 
determined by 15-fold measurements, on consecutive days, of plasma samples of 14 pg/ml, 37 
pg/ml, and 161 pg/ml and were found to be 15.2%, 15.1%, and 8.0 % respectively (Table 18). 
Non-extracted saliva samples which were measured at 9, 18, and 89 pg/ml had inter-assay 
coefficients of variation at 27.6, 14.4, and 11.4% respectively (Table 19). 
 
 High Pool Medium Pool Low Pool 
 144 34 19 
 146 37 22 
 138 34 19 
 141 32 17 
 145 33 18 
 128 33 17 
 134 35 16 
 132 34 17 
 134 33 19 
 132 34 18 
mean 138.8 33.5 18.1 
std dev 6.1  2.1 1.3 
%CV 4.4 6.3 7.3 
 
Table 17.  Intra-assay CV for A2E11 antibody on extracted plasma samples (duplicate values). 
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 High Pool Medium Pool Low Pool 
 155 32 16 
 168 28 15 
 151 33 10 
 141 37 11 
 163 37 16 
 170 38 14 
 162 38 14 
 170 43 18 
 157 46 12 
 152 45 14 
 174 32 13 
 145 43 14 
 161 41 14 
 152 35 12 
 192 29 16 
mean 160.8 37.1 13.9 
std dev 12.9 5.6 2.1 
%CV 8.0 15.1 15.2 
 
Table 18.  Inter-assay CV for A2E11 antibody on extracted plasma samples (singlicate values) 
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 High Samples Pool 
Medium 
Samples  Pool 
Low 
Samples Pool 
 84 16 9 
 90 20 9 
 91 17 9 
 84 15 7 
 72 17 11 
 72 17 7 
 104 20 12 
 87 18 9 
 100 15 8 
 104 15 11 
 83 23 9 
 101 22 11 
 88 18 7 
 93 18 12 
 84 21 9 
mean 89.1 18.1 9.3 
std dev 10.2 2.6 1.7 
%CV 11.4 14.4 18.4 
 
Table 19. Inter-assay CV for A2E11 antibody on non-extracted saliva samples (singlicate values). 
 
 
 
3.4.  Salivary aldosterone determination with and without the Sarstedt salivette 
Samples of saliva which were collected without the use of the Sarstedt salivette had aldosterone 
levels which were highly correlated to those obtained by using the device (y = 1.0044x – 2.28; 
R2 = 0.9057).   
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3.5.  Pre-analytical storage stability of saliva samples 
Aldosterone was stable if the saliva was kept in the original Sarstedt Salivette after both storage 
at room temperature as well as at 4°C for up to 7 days (Figure 16).  In one of the saliva samples 
stored at ambient temperature within the salivette aldosterone showed a tendency towards 
increased values after 7 days, the study was not continued further after this point.  4°C would 
therefore be recommended when storing for longer periods.  Saliva aliquoted and stored at 4°C in 
the eppendorf cups was also stable for up to one week.  The salivary aldosterone levels were not 
stable however, when stored in eppendorfs for one week at room temperature.  Increased values 
were seen as soon as after 3 days for two of the samples (subject 4 and 5) while for the remaining 
samples the increase was clear at 7days. 
Figure 16. Stability of aldosterone in saliva, measured using the Acris assay, after storage in salivettes at 
room temperature and at 4°C, and after aliquoting and storage in eppendorf cups at room temperature and 
at 4°C. 
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3.6.  Correlation of calibrators with commercially available RIA 
In-house aldosterone calibrators (0 to 2000pg/ml) were added in two separate runs as samples 
and measured with the DPC Biermann (Coat-A-Count) radioimmunoassay and mean values were 
taken.  Though the correlation between the two assays was very high, the in-house calibrators 
were measured by the DPC assay at approximately one third the value assigned in-house and 
therefore the first four calibrators (5 to 50 pg/ml) were not measurable in the linear range of the 
DPC assay (y = 0.27x, R2 = 0.98; Figure 17, Table 20).  
Figure 17.  In-house aldosterone standards used for the Acris assay as observed by the DPC RIA kit 
when added as samples and measured in a typical assay. 
 
In-House Std Curve DPC measurement 
 Run 1 Run 2 mean 
0 out out out 
5 out out out 
10 out out out 
20 out out Out 
50 out out Out 
100 11.6 4.5 8.1 
200 52.9 75.2 64.1 
500 213.6 221.4 217.5 
1000 388.6 384.4 386.5 
2000 694.6 696.3 695.5 
 
Table 20.  DPC assessment of in-house Acris assay aldosterone calibrators. 
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Measurement of the DPC calibrators in the Acris assay corresponded to a factor of almost two 
times higher than the value given by the manufacturer (y = 1.73x + 6.9, R2 = 0.981; Figure 18, 
Table 21), and after extraction of those calibrators using dichloromethane there was a decrease in 
the correlation to 0.71 (y = 0.71x – 14.0, R2 = 0.989), where y = in-house assessment of the x 
DPC given concentration.   
 
Figure 18.  Correlation of DPC calibrators as measured by the in-house Acris assay before and after 
extraction (solid line=no extraction, dotted line=after extraction). 
 
 DPC calibrators 
(pg/ml) 
In-house assay 
(pg/ml) 
In-house assay after 
extraction (pg/ml) 
A 0 112 23 
B 25 104 23 
C 50 101 35 
D 100 173 48 
E 200 275 75 
F 600 859 382 
G 1200 2190 867 
 
Table 21.  DPC calibrators as measured by the in-house Acris assay before and after extraction. 
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Extraction and assessment of the calibrators using the A2E11 assay revealed a measurement by 
the in-house assay at around 60% that stated by DPC, with the relationship approaching 1:1 at 
higher concentrations due to the fact that concentrations lie within the linear portion of the curve 
in both assays (Figure 19, Table 22). 
 
 
Figure 19.  Correlation of DPC calibrators as measured by the in-house A2E11 monoclonal antibody 
assay after extraction (calibrator G not included as not in linear range of in-house assay, see Figure 24). 
 
 
 
 DPC calibrators (pg/ml) 
In-House assay after 
extraction (pg/ml) 
A 0 14 
B 25 21 
C 50 31 
D 100 44 
E 200 135 
F 600 593 
G 1200 665 
 
Table 22.  DPC calibrators as measured by the in-house A2E11 assay after extraction. 
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3.7.  Extraction of saliva and plasma– Acris assay 
3.7.1.  Salivary aldosterone  
After evaluation of 188 saliva samples before and after extraction, results following extraction 
were highly correlated at around 80% of aldosterone measured without pre-treatment (y = 
0.7877x, R2 = 0.75; Figure 20a, b, c, and d).  Due to this high correlation and in order to 
minimize inter-assay CV’s it was decided not to include the extraction procedure apart from 
situations where there were suspiciously high samples.  Peaks at around 10am and 2pm in the PA 
patient are due to testing carried out as part of a study and corresponded to a physiological 
increase in the first case and an increase in response to ACTH stimulation in the second.  There 
is an increase around mid-afternoon in both of the healthy participants which has also previously 
been reported by other authors and may be in response to normal daily rhythms.  Levels do not 
differ overall between the healthy participants and the suspected aldosteronism patient in this 
case. 
 
3.7.2.  Plasma aldosterone 
Plasma samples tested for aldosterone content using the Acris assay with incorporation of the 
extraction method and comparison with values given by the DPC assay showed that there was an 
excellent correlation between the two assays (y = 1.007x + 16.236, R2 = 0.85, n = 46, Figure 21 
and 22).  Using a reduced volume of 100µl, with assay values multiplied by a factor of 2, yielded 
aldosterone values that were at around 70% the value obtained by the in-house assay after 
extraction of 200µl and at approximately 80% those of the DPC RIA (Figure 23a and b).  
Though recovery was not complete the values still remained highly correlated (y = 0.7049x + 
2.689 and y = 0,7942x -7.2087, R2 = 0.91 and 0.88, respectively; Figure 24a and b).   
 99
 
 
Figure 20. a, b and c.  Daily saliva aldosterone profiles in two healthy participants and one suspected  
PA patient before and after extraction (200µl) as measured by the Acris in-house assay. d.  Correlation 
before and after extraction of saliva samples as measured by the Acris assay. 
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Figure 21.  Daily plasma aldosterone profiles in healthy participants after extraction (200µl) as measured 
by Acris in-house assay compared to DPC assay. 
 
 
 
 
Figure 22.  Correlation of plasma samples as measured by the Acris assay after extraction of 200µl of 
plasma and the DPC assay which incorporates no extraction step. 
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Figures 23a and b.  Reduced volume plasma extraction for measurement in the Acris in-house assay 
compared to measurement by the DPC in two healthy participants. 
 
 
 
 
 
Figures 24a and b.  a) Correlation between the standard volume used and the reduced 100µl and b) 
correlation for reduced volume plasma extraction and the measurement by the DPC in two healthy 
participants. 
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3.8.  Extraction of plasma– A2E11 assay 
Figures 25a, b, and c show the results of aldosterone measurements after plasma extraction using 
the A2E11 antibody assay using a smaller volume of 50µl.  Using the standard volume it was 
ascertained that measurement of plasma aldosterone is possible, however at a lower level overall.  
When the smaller volume of plasma was used aldosterone values were still highly correlated to 
the DPC assay (R2 = 0.97) and increases and decreases in response to various stimuli were 
clearly visible.  Measurements were at a lower concentration of approximately 80% of those 
given by the DPC (y = 0.7951x – 33.9). 
Figure 25 a, b, and c.  Reduced volume plasma extraction (50µl) for measurement in the A2E11 in-house 
assay compared to measurement by the DPC in two healthy participants. 
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3.9.  Salivary Aldosterone - Acris assay clinical validation 
3.9.1.  Day Profile Study results – saliva and plasma  
Mean saliva values (±SEM) for 9 healthy participants (demographics Table 23) ranged from 91 ± 
19pg/ml in the morning to 49 ± 5pg/ml at 6pm and plasma values from 157 ± 35pg/ml to 80 ± 
22pg/ml (Figure 26), showing the general trend of increased levels in the morning that decrease 
during the course of the day, which has also previously been reported for healthy participants by 
several authors (Hurwitz et al., 2004; Few et al., 1987; Takeda et al., 1984; Chavarri et al., 1977;  
Katz et al., 1975).  Though the salivary aldosterone decrease was not as pronounced as that seen 
in plasma, values were significantly lower at 6pm compared to the 8am values (p<0.05, 
significance calculated by Wilcoxon paired t-test) as were plasma values at 6pm to 8am 
(p<0.01). 
Figure 26.  Mean (± SEM)  saliva and plasma values for 9 healthy participants.  Saliva values measured 
by Acris assay and plasma values measured by DPC RIA.  
 
 Male Female 
n 4 5 
Age (yrs) 35 ±  9.35 24 ±  2.35 
BMI 23.7 ±  2.0 20.6 ±  1.2 
OC n/a 2/5 
Table 23. Data are shown as mean  ± SD.  n, No. of  participants; OC, Oral Contraceptive;  All 
participants were non-smokers. 
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3.9.2.  Mean levels in Primary aldosteronism and healthy participants 
After measurement of 201 samples from confirmed PA patients, collected from patients admitted 
to the clinic, not taking any medication at the time of sampling, and 203 samples from healthy 
subjects and volunteers, baseline mean salivary aldosterone values, as measured by the Acris 
antibody assay, yielded concentrations of 120 ± 4pg/ml and 59 ± 2pg/ml respectively (p<0.0001, 
significance calculated by Mann-Whitney U test; Figure 27).   
 
Figure 27. Salivary aldosterone levels in Primary aldosteronism and healthy participants.  Mean value for 
PA = 120 pg/ml (n = 201) and for healthy participants =59 pg/ml (n = 203).  Bars indicate 25th and 95th 
percentiles for each group with individual outliers given above and below; significance was calculated by 
Mann-Whitney U test, *p<0.0001. 
 
Figure 28 shows mean salivary aldosterone values (±SEM) from nine PA patients collecting day 
profiles every four hours.  Levels were sustained at a high concentration all day and did not vary 
between different time points (Kruskal-Wallis non-parametric test, p = 0.961).  Similarly, 
salivary aldosterone samples collected from eight healthy participants between the hours of 
8:45am and 15:45pm did not vary significantly though there seems to be an apparent increase 
between 10:45 and 11:00 and a tendency to decrease overall, although these were not found to be 
statistically significant (Figure 29, Kruskal-Wallis, p = 0.695).   
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Figure 28. Daily profile of salivary aldosterone levels from eight patients with Primary aldosteronism, as 
measured by the Acris assay.  Data is shown as mean (±SEM). 
 
 
Figure 29. Daily profile of salivary aldosterone levels from eight healthy participants, as measured by the 
Acris assay.  Data is shown as mean (±SEM). 
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3.10.  Salivary aldosterone TRFIA measurements compared to plasma measured with a 
commercial RIA 
After a measurement of a total of 912 paired saliva and plasma samples from PA patients and 
healthy control subjects, by the in-house TRFIA incorporating the Acris polyclonal antibody and 
the DPC RIA respectively, it was determined that aldosterone exists in saliva at around 28% that 
found in plasma, although there is considerable variability in this relationship, in accordance 
with previously reported correlations by other authors (McVie et al., 1979; Hubl et al., 1983; 
Few et al.,1984; Atherden et al.,1985) (Figure 30, y = 0.275x + 54.6, R2 = 0.5738). 
 
Figure 30.  Correlation between the Acris aldosterone in saliva assay and the DPC aldosterone in plasma 
assay after measurement of 912 paired samples. 
 
3.11.  Posture test study 
There was a significant increase in peak levels of salivary and plasma aldosterone after change in 
posture at 1hour following standing, when compared to mean baseline values at 2hours following 
a supine posture, (p<0.0001, Figure 31).   Within the first hour after standing mean (±SEM) 
salivary aldosterone levels increased from 55 ± 4 pg/ml to 100 ± 8 pg/ml, while plasma levels 
also showed a marked increase from  33 ± 4 pg/ml to 145 ± 17 pg/ml.  Salivary aldosterone 
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mirrored the increase seen in plasma with levels at approximately 26% of plasma (y = 0.259x + 
52.38, where y= saliva and x= plasma).   
 
Figure 31.  Mean (±SEM) salivary and plasma aldosterone responses to posture, as measured by the 
Acris in-house and DPC assays respectively, in 32 participants. 
 
Figure 32a and b.  Salivary and plasma aldosterone response to posture reached a higher value in 
females compared to males after change in posture. 
 
Peak aldosterone after change in posture was clearly higher in females than in males, but 
independent of oral contraceptives (data not shown), in both salivary and plasma samples (Figure 
32a and b). Univariate analysis showed there was an overall main effect of sex in plasma 
aldosterone, p= 0.028, females 99 ± 11 pg/ml compared to males at 63 ± 11 pg/ml (Fig 48b).  In 
salivary aldosterone univariate analysis showed there was no main effect of sex (p= 0.230), 
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although there was a time by sex interaction, p= 0.032, due to the increased values following the 
posture change in the females. 
No difference in plasma aldosterone levels of smokers was found compared to the non-smokers 
(p= 0.669, univariate analysis).  In salivary aldosterone univariate analysis showed there was a 
significant main effect of smoking (p=0.004) whereby smokers had a mean overall of 86 ± 6 
pg/ml compared to a mean of 62 ± 5 pg/ml in the non-smokers (Figure 33b and a respectively).  
 
Figure 33a and b.  Salivary and plasma aldosterone response to posture was higher overall in smokers 
compared to non-smokers at all time points.  Similar results were not seen in plasma aldosterone between 
smokers and non-smokers. 
 
3.12.  ACTH stimulation test 
In healthy participants mean baseline salivary aldosterone (SA) concentrations were 67 ± 7 
pg/ml.  After ACTH stimulation, mean SA were 128 ± 19 pg/ml, 121 ± 10 pg/ml, and 113 ± 14 
pg/ml at 75, 105, and 135 minutes, respectively (Figure 34a).  SA was significantly higher than 
basal at 75 and 105 (p<0.005), and 135 (p<0.02) minutes after ACTH stimulus.  Most 
participants reached maximal aldosterone concentrations at 75 minutes after stimulation.  
Healthy participants showed a mean, max response increase of 61 ± 12 pg/ml at 75 minutes.  
Simultaneous plasma samples were taken and basal plasma aldosterone (PLA) concentrations 
determined using the DPC RIA were at 52 ± 10 pg/ml.  After ACTH stimulation, mean PLA 
were 167 ± 24 pg/ml, 148 ± 23 pg/ml, and 136 ± 19 pg/ml at 75, 105, and 135 minutes, 
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respectively.  As in the saliva samples, peak response was at 75minutes and declined thereafter 
and was statistically significant at each time point (p< 0.005, p< 0.01, and p<0.005 respectively).  
Statistical significances were calculated by Mann-Whitney un-paired t-test. 
 
Figure 34a and b.  Mean (± SEM) saliva and plasma aldosterone concentrations for normal healthy 
volunteers (upper panel) and suspected Conn’s patients (lower panel) after stimulation with ACTH 
(250µg; Synacthen Novartis).  * p<0.02, ** p<0.005 significant increase compared to baseline. 
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SA concentrations at 105 and 135 minutes after stimulation, although the means of the two 
groups were not significantly different.  PA participants showed a mean, max response increase 
of 143 ± 14 pg/ml at 105 minutes.  Simultaneous plasma samples had basal PLA concentrations 
at 177 ± 47 pg/ml.  After ACTH stimulation, mean PLA were 449 ± 97 pg/ml, 440 ± 91 pg/ml, 
and 402 ± 81 pg/ml at 75, 105, and 135 minutes (Figure 50b).  Peak response was at 75minutes 
and declined thereafter and was statistically significant at each time point (p< 0.01, p< 0.01, and 
p<0.02, respectively).  All statistical significances between groups were calculated by Mann-
Whitney unpaired t-test. 
 
3.13.  Salivary Aldosterone to Cortisol Ratio 
Our data in 27 PA subjects and 41 controls showed that the overall aldosterone to cortisol ratio 
(ACR ± SEM) was 0.180 ± 0.039 in PA compared to 0.033 ± 0.003 in controls (p < 0.0001, 
Figure 35a).  The ACR is higher in the evening compared to daytime due to lower variation in 
aldosterone values together with decreasing cortisol. 7–12 am values in the PA patients yielded a 
ratio of 0.074 ± 0.01 compared to 0.318 ± 0.081 between 6–10pm. In the controls this difference 
is less pronounced, 0.021 ± 0.004 compared to 0.047 ± 0.004 in the evening (Figure 35b).   
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Figure 35a and b.  a)  Salivary aldosterone to salivary cortisol ratio (ACR) in Primary aldosteronism 
(PA; n = 53) and healthy control subjects (n = 60) b) ACR according to the diurnal variation seen with 
morning and evening sampling times. 
 
 
 Primary Aldosteronism Healthy subjects 
 morning evening morning evening 
ACR 0.019  to 0.268 (avg  0.074 ± 0.010 ) 
0.093  to 1.762 
(avg 0.318 ± 0.081 ) 
0.004  to 0.086 
(avg 0.021 ± 0.004 ) 
0.013  to 0.098 
(avg 0.047 ± 0.004 ) 
SA 
(pg/ml) 
35  to 368 
(avg 96 ± 13 ) 
22  to 527 
(avg 130 ± 28 ) 
20  to 109 
(avg 59 ± 4 ) 
19  to 79 
(avg 42 ± 3 ) 
SF 
(pg/ml) 
324  to 4308 
(avg 1618 ± 170 ) 
155  to 942 
(avg 426 ± 44 ) 
843  to 14600 
(avg 5079 ± 622 ) 
300  to 3200 
(avg 1174 ± 154 ) 
N 30 23 33 27 
 
Table 24.  Summary of results from salivary ACR, salivary aldosterone (SA) and salivary cortisol (SF) in 
Primary aldosteronism and healthy subjects. 
 
The overlap in salivary ACR seen between PA and healthy subjects in the morning is abolished 
in the evening.  Levels are almost completely separated with only 1 out of 23 samples from PA 
below the upper limit of the control subjects (0.098).  Therefore, at physiological conditions, a 
ratio higher than 0.1 at late night is suggestive of Primary aldosteronism.  Post-ACTH 
stimulation test the ACR decreased in the 10 PA to 0.015 ± 0.003 and to 0.014 ± 0.005 in the 
controls, compared to 0.104 ± 0.023 and 0.051 ± 0.009 at baseline respectively, due to the 
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approximately 10-fold increase in the levels of SC compared to the less pronounced increase in 
SA (Figure 36).  
 
 
Figure 36.  Salivary ACR in PA and healthy subjects after stimulation of the pituitary adrenal axis with 
ACTH is clearly diminished making it impossible to distinguish between the two groups. 
 
Un-stimulated baseline SA was at an average of 111 ± 14 pg/ml in PA patients and 52 ± 3 pg/ml 
in controls (Figure 37). The overlap in salivary aldosterone between PA and controls remains  
 
Figure 37.  Salivary aldosterone concentrations in Primary aldosteronism (PA) patients and healthy 
subjects. Morning and evening do not change significantly from morning to evening in the aldosteronism 
patients compared to controls where there is significant decrease (p<0.005).  
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even when evening samples are taken, although levels are overall significantly higher in the PA 
patients (p< 0.0001).  SA and salivary cortisol (SF) (data not shown) levels both decreased 
throughout the day in the control subjects in accordance with expected circadian rhythms.  
Though there was a drop in SF in PA subjects, the decrease in SA was not observed, as would be 
expected with an autonomous hypersecretion of aldosterone.  
 
3.14.  A2E11 assay salivary aldosterone clinical validation 
There was a highly positive correlation between the salivary aldosterone measurements given by 
the Acris assay to those given by the A2E11 assay (R2 = 0.94), after measurement of 28 salivary 
samples, described by the equation y = 2.7x + 25.7 whereby aldosterone measured using the 
Acris assay gave values that were approximately three times those measured by the A2E11 (with 
a positive bias of 25.7, Figure 38).  
 
Figure 38.  Correlation between measurement of aldosterone by the two in-house saliva assays (n = 27). 
 
3.15.  A2E11 assay – validation in rodent serum/plasma 
3.15.1.  Basal aldosterone in male and female wild type mice 
Values from all wild-type animals used in the study were examined in order to determine gender 
differences which may be present in mice.  There was no overall significant difference (p = 
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0.396) found between female (n = 35) and male (n = 40) mice, whose serum values had mean (± 
SEM) levels of 163 ± 34 pg/ml and 181 ± 27 pg/ml, respectively (Figure 39).  
 
Figure 39.  Mean serum aldosterone levels in female and male WT mice (n = 35 and n = 40 respectively).  
Bars indicate 25th and 95th percentiles for each group and significance was calculated by unpaired t-test. 
 
In addition, there was no sex difference in any particular age group (p>0.05 at 3, 5, 7, 9 and 11 
weeks, Table 26).  Since no gender-dependent differences in serum aldosterone levels were 
observed throughout the studied points of time, aldosterone values for female and male mice 
were averaged at the different points of time (week 3: n = 8, week 5: n = 8, week 7: n = 27, week 
9: n = 12 and week 11: n = 20; Figure 40, Table 25) and found to have mean (± SEM) 
aldosterone concentrations of 52 ± 9 pg/ml, 57 ± 11 pg/ml, 272 ± 45 pg/ml, 107 ± 33 pg/ml, and 
174 ± 34 pg/ml respectively.  The Kruskal-Wallis non-parametric test displayed an overall 
significance between the groups (χ2 = 18,98; df = 4; p = 0.001).  No significant difference in 
aldosterone levels was found between weeks 3 and 5 (p = 0.753). At an age of  7 weeks 
aldosterone rose by 377% compared to the 5-week old mice (p = 0.003).  Although there was a 
drop at week 9, serum aldosterone concentrations remained high overall and were not 
significantly different between 9 and 11 weeks (p = 0.115).  At week 11 the aldosterone levels 
were still significantly higher than at both weeks 3 and 5 (p = 0.007 and p = 0.011). 
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Figure 40.  Mean (±SEM) serum aldosterone levels in male and female WT mice at indicated weeks of 
development.  3 weeks (n = 8), 5 weeks (n = 8), 7 weeks (n = 27), 9 weeks (n = 12) and 11 weeks (n = 
20).  Significances were determined by Kruskal-Wallis and unpaired t-test. 
 
 
 
 
 
 
 
 
Table 25. Serum aldosterone concentrations in female and male mice at increasing weeks of 
development.  There was no significant difference between the male and female mice throughout the 11 
weeks. 
 
weeks p 
3 - 5 0.753 n.s. 
5 - 7 <0.005 
5 - 9 0.354 n.s. 
7 - 9 <0.05 
7 - 11 0.220 n.s 
9 - 11 0.115 n.s 
5 - 11 <0.05 
 
Table 26. Statistical significance between the different age groups of mean male and female mice values. 
 
Age (weeks) Female Male  
 n aldosterone 
(pg/ml) 
n aldosterone 
(pg/ml) 
p 
3 4 54 ± 9 4 51 ± 17 0.773 
5 4 73 ± 16 4 42 ± 10 0.149 
7 12 277 ± 77 15 268 ± 54 0.807 
9 6 61 ± 15 6 154 ± 62 0.174 
11 9 170 ± 62 11 178 ± 37 0.569 
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3.15.2.  Suppression and stimulation in wild type mice 
Kruskal-Wallis non-parametric test showed an overall significance between the three groups of 
control, dexamethasone suppressed, and ACTH stimulated mice (χ2 = 15.866; df = 2; p < 0.001; 
Figure 41).  Animals treated with dexamethasone had significantly lower concentrations of 
aldosterone (35 ± 3 pg/ml) than the control mice (114 ± 33 pg/ml; p = 0.021). 6 out of the 7 mice 
treated with dexamethasone suppression had values below the LOD (8 pg/ml).  For the 
calculation of the mean, all these values were assigned a concentration of 8 pg/ml. Mice 
stimulated with ACTH showed significantly elevated values compared to the control group (603 
± 119 pg/ml; p = 0.003).   
 
Figure 41.  Mean (±SEM) serum aldosterone levels in grouped male and female WT mice 
treated with 10 days dexamethasone, 10 days NaCl (control group), and 10 days Synacthen 
ACTH.  Significance compared to baseline control group determined by unpaired t-test. 
 
 
3.15.3.  Effect of an increased potassium diet – stimulation/suppression of adrenal RAAS 
Serum samples measured from mice sustained on a high K+ diet had mean aldosterone values of 
1369 ± 703 pg/ml, the control group had a mean of 172 ± 36 pg/ml, and the low K+ diet animals 
287 ± 60 pg/ml, as measured by the in-house TR-FIA.  The aldosterone values from the high K+ 
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group were significantly higher than those of the control group (p= 0.0025) while the control and 
low K+ groups did not differ (p= 0.142, Figure 42).  Similarly, the same samples from the same 
groups of mice when measured with the commercial DPC RIA kit gave values of 1744 ± 697 
pg/ml, 294 ± 65 pg/ml, and 407 ± 76 pg/ml in each respective group.  Again, the high K+ fed 
animals were significantly higher compared to the controls (p= 0.0009) and the low K+ were not 
statistically significantly higher (p= 0.369). 
 
 
Figure 42. Aldosterone values in plasma of mice maintained on high and low potassium diets 
obtained using a) the A2E11 monoclonal antibody assay and b) the DPC RIA. 
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4.  Discussion  
 
4.1.  Aldosterone in hypertension, Primary aldosteronism 
The Renin Angiotensin Aldosterone System (RAAS) is the main effector mechanism in 
the equilibrium between vascular tone and intravascular filling pressure.  It is activated if sodium 
intake is low and/or if intra-arterial volume and filling pressure fall.  The RAAS maintains 
arterial pressure by increased angiotensin-induced constriction of vascular smooth muscles and 
increased angiotensin-induced stimulation of aldosterone thereby leading to sodium retention 
(Gavras & Brunner, 2007) and increased extracellular fluid volume.  Cardiac hypertrophy, 
regulated by ventricular pressure and volume loading, and perivascular fibrosis have been 
positively correlated with the effector hormones of the RAAS (Takeda et al., 2000).  Increased 
circulating levels of the mineralocorticoid aldosterone, the final hormone in the RAAS cascade, 
and its presence along with other components of the RAAS within cardiac tissues, are implicated 
in leading to tissue remodelling, heart failure and hypertension.  An extensive amount of 
evidence links increased levels of aldosterone, even within physiological ranges, to the 
pathogenesis of hypertension in humans (Vasan et al., 2004).  Evidence coming from recent 
large scale studies such as RALES and EPHESUS renewed interest in the role of 
mineralocorticoids in cardiovascular disease and in the risk of developing high blood pressure 
and showed the benefits of aldosterone blockade with mineralocorticoid receptor antagonists 
spironolactone and eplerenone, respectively, in patients with chronic heart failure (Pitt, 2004).  
Primary aldosteronism, where excess levels of aldosterone exist, most commonly due to an 
adrenal adenoma or to bilateral adrenal hyperplasia, is the most common form of essential 
hypertension and is now known to occur in approximately 10-15% of suspected patients 
(Stowassser et al., 2003; Young, 2003; Giacchetti et al., 2006). 
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This increase in recent years in the diagnosis of PA, justifies the development of widely 
applicable and easy to perform screening methods combining high levels of sensitivity for 
detecting increased levels of aldosterone in a wider range of suspected subjects who could then 
benefit from anti-mineralocorticoid treatment.  The use of saliva as a diagnostic specimen has 
been used since the 1980s for the detection of steroid hormones such as cortisol, testosterone, 
estradiol and progesterone.  However, measurement of salivary hormones can only be clinically 
relevant if they truly reflect the serum or plasma hormone levels or if a constant relationship 
exists between the concentrations in the two parameters.  For neutral steroids which simply 
diffuse into saliva through epithelial cells, salivary hormones represent the free, non-protein 
bound serum hormone levels (Vining et al., 1983), which may be clinically relevant since it is 
this fraction which is biologically active.  Salivary monitoring of hormones has many advantages 
compared to restraints imposed by serum or plasma analysis and the demanding 24hour urinary 
collection.  It allows multiple sample collection in short intervals due to its non-invasive nature 
and sampling without supervision throughout the day removing the need to visit a specialized 
centre.  In 1982 investigators showed that salivary cortisol levels correlate extremely well with 
free serum cortisol and since then many assays, mostly radioactive to begin with, have appeared 
for other steroid hormones (Kaufman & Lamster, 2002).   
 
4.2.  Aldosterone in saliva – application of the assay 
The first report of a salivary aldosterone assay comes from the late 1970s but even 
preceding this authors had described the protein-free as opposed to protein-bound levels of 
aldosterone in plasma (McVie et al., 1979).  Free levels existing at around 30-40% of bound and 
at a ratio of 0:2-0:3 (Few et al., 1986).  Although some studies exist on a putative specific 
binding protein of aldosterone in plasma (Davidson et al., 1962), there has been no specific 
protein named until now.  The same ratio of salivary to plasma aldosterone does not always exist 
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between all individuals and one reason for this may be that aldosterone concentrations are 
relatively low overall and therefore more likely to be affected by changes in binding proteins, 
although aldosterone is known to be weakly bound to proteins and exists at reasonably high free 
concentrations in serum and is therefore relatively unaffected (Few et al., 1986).     
The low concentrations of aldosterone, compared to other hormones such as cortisol 
which is present at around 1000 times the concentration, has meant that previous assays have 
required large volumes of up to 2ml  for each sample (Few et al., 1987).   Alternatively, in one 
reported case the authors adjusted a commercially available assay designed for plasma level 
assessment, by increasing the volume twofold to 400µl (Cardoso et al., 2002).  The assay 
described and validated here requires a small sample volume of 100µl for each duplicate 
measurement.  Furthermore, it was established that results for salivary aldosterone correlate 
extremely well before and after extraction with DCM, and as this step is also often responsible 
for increasing inter-assay variability of results, it was decided that this step should be omitted.  In 
cases where samples showed particularly high aldosterone values this step was applied to ensure 
that values are not increased due to interference from other cross-reacting substances.   
Many of the previously established assays required not only extraction with DCM but 
also chromatographic purification (Hubl et al.,1983; McVie et al., 1979), and incorporated 
radioactively labelled tracers in the detection system (Few et al., 1987; Atherden et al., 1985).  
We have developed a non-isotopic immunoassay, avoiding the frequent production and between-
assay variability of radioactive tracers, as well as the environmental, health, and practical aspects 
involved.  The tracer used in our assay was designed according to a previously validated method 
for biotinylating steroids, providing practically unlimited stability and a “specific activity” which 
is not affected by storage time (Dressendorfer et al., 1992).  
A further advantage offered by the non-radioactive, non-enzyme linked, biotinylated 
aldosterone tracer is that the biotin conjugate produced is of a relatively comparative size, 
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726.5Da, to the analyte and chances of binding to the anti-aldosterone antibody coated to the 
surface of the microtitre plate well are similar between the analyte and the tracer. 
 
4.3.  Establishment of the assay 
The chromatographic technique used to purify the biotinylated aldosterone conjugate was 
reverse phase high performance liquid chromatography, chosen due to the non-polar nature of 
the adsorbant material of the column, octadecyl (C18) ligand-bonded silica, ideal for binding 
small neutral molecules such as steroids.   In this type of set-up the eluent’s polarity plays an 
important role in the retention time and separation of the compound injected.  For this reason two 
different types of elution profile were assessed, one in gradient, where the polarity of the solvent 
is steadily decreased, as well as an isocratic gradient pumped through the column equally during 
the whole analysis. The gradient approach, with increasing concentrations of methanol and 
acetonitrile respectively, was applied to both of the two different columns purchased from 
companies ‘Knauer Advanced Scientific Instruments’ and ‘Phenomenex®’, while the isocratic 
gradient only was applied using the Phenomenex column.  Chromatography runs using the 
Knauer column yielded major peaks at approximately 80 minutes, with several smaller peaks 
occurring at around 60 minutes, presumably representing the elution of more polar educts still 
present in the sample, such as that due to the molar excess of biotin which was added to ensure 
complete biotinylation of the aldosterone-3CMO molecule.  The fractions collected from this 
column yielded a tracer molecule with high specificity but concentrations were lower than those 
obtained by the Phenomenex column purification therefore further analysis was not carried out 
with this column.  Use of an isocratic gradient as opposed to a linear gradient, with the 
Phenomenex column, yielded better separation of fractions containing higher concentrations of 
aldosterone with lower non-specific binding due to a lower amount of biotin still present in the 
solution, as was seen by fraction 51/52 of Phenomenex Run 3 and fraction 40 of Phenomenex 
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Run 4 which combined highest yield of concentrations, 1431ng/ml and 2190ng/ml respectively, 
and gave the highest displacement at 20pg/well of 54 and 46%.    
 During the course of the studies to validate the aldosterone assay for measurement in 
saliva, the opportunity arose to obtain a highly sensitive and specific monoclonal antibody 
against aldosterone from the University of Mississippi Medical Center (Jackson, Mississippi, 
USA.).  Therefore, whilst continuing the ongoing studies with human saliva samples using the 
polyclonal antibody, development of an assay incorporating the monoclonal was likewise carried 
out.  The superior sensitivity of the monoclonal antibody was taken advantage of in designing the 
assay method in order to measure aldosterone in small volumes of serum or plasma taken from 
small rodents.  The polyclonal, commercially available anti-aldosterone antibody (Acris 
Antibodies GmbH, Hiddenhausen, Germany) was used to establish optimum conditions, such as 
concentration and incubation time necessary for optimum binding, for running the assay to 
measure aldosterone concentrations in saliva samples.  Decreasing the concentration of the tracer 
approximately ten-fold as well decreasing the concentration of the antibody gave a significant 
increase in the sensitivity of the assay, sufficient to bring the measurable range of the assay down 
to 19pg/ml for each 50µl sample (well within the range of normal values and allowing distinction 
between healthy participants and those with PA).  In combination with the monoclonal antibody 
the same tracer fraction from the Phenomenex run which was chosen for all consequent assay 
runs, gave a lower detection limit of 8pg/ml, yielding an even more sensitive assay.   The tracer 
has been used and stored in our laboratory for 24 months without loss of activity. 
The differences seen between the two assays using the two antibodies are to be expected 
when comparing the binding characteristics of a polyclonal compared to a monoclonal antibody.  
Discrepancies arise due to the methods involved in production of the antibodies. Whereas a 
polyclonal antibody involves the immune response of an individual immunized animal and will 
contain a heterogeneous mixture of antibody species of varying specificity, recognizing more 
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than one epitope, a monoclonal is derived from a specific clone which is isolated and expanded 
to produce antibodies which are homogenous and uniform in nature, with unique characteristics, 
epitope specific and with a fixed affinity.   
The specificity of the monoclonal antibody had previously been certified when its 
production was published in 1987 by Gomez and co-workers (Gomez-Sanchez et al., 1987).  
Although the polyclonal antibody was checked for cross-reactivity with certain endogenously 
found steroids by the manufacturer, it was further verified in our laboratory and found to cross-
react below 0.01% for endogenous and synthetic steroids.  Cortisol, for example, which cross-
reacts by only 0.004% with this antibody would require a concentration in the high microgram 
range in order to see an altered value in the aldosterone reading, unlikely since in the blood it 
rises to 0.25µg/ml even at peak levels.  A concentration of a similar magnitude would be needed 
to interfere substantially with assay values in the case of progesterone which cross-reacted at 
0.005% and is present at 26ng/ml at its highest luteal phase levels (Laycock & Wise, 1996). 
 Both the monoclonal and polyclonal assay were fully validated according to linearity, 
recovery, and reproducibility requirements.  Measurements of human saliva samples were further 
validated after an extraction step using the solvent dichloromethane to remove any potentially 
interfering substances.  The accuracy of the assay was confirmed by the excellent agreement of 
results obtained by the direct assay for saliva with those determined after extraction, and by 
plasma sample results obtained after extraction step which were compared to a commercial 
radioimmunoassay (DPC, Biermann) for measurement of plasma aldosterone levels.  
 
4.4. Clinical validation 
4.4.1.  Salivary aldosterone monitors changes in plasma 
Values for salivary aldosterone correlated well to those measured in concurrently 
obtained plasma samples as assesses by the DPC RIA. Assessment of the DPC calibrators using 
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the polyclonal antibody assay demonstrated that there are certain non-specific matrix effects 
occurring due to components present in the calibrators and interfering with the capture antibody.  
These interfering substances are not extracted into the DCM phase with values more closely 
correlated after extraction.  With the monoclonal antibody assay there was a linear relationship 
with the calibrators after extraction. The naturally occurring low levels of aldosterone and the 
difference in calibrators of the two assays means that there is some overlap seen in the plasma 
and saliva values of the healthy participants at the lower range.  This would also explain the 
differences in basal values reported by ourselves and some other investigators who report 
baseline values of 34.5pmol/L (12pg/ml) in healthy subjects (Cardoso et al., 2002).     
Previous authors have suggested that frequency of sampling should be at least once an 
hour in order to detect short-term fluctuations in hormone levels which in aldosterone occur 
hourly, five samples per day giving a reasonable estimate of mean diurnal concentrations (Few et 
al., 1986).  Though we did not collect samples as frequently as every hour we did observe from 
individual cases of sampling every two hours that salivary aldosterone indeed varies throughout 
the day and is often not found at its highest levels in the morning, as aldosterone is easily 
influenced by many external factors, such as diet and stress, and the regulation of its secretion is 
complex.  Mean salivary aldosterone levels from 9 participants did show highest levels at 8am in 
the morning of 91pg/ml (255pmol/L) which decreased to significantly lower concentrations by 
6pm, 49pg/ml (137pmol/L), and followed the pattern measured in concurrently collected plasma 
samples.  This data is in agreement with previous observations on the circadian rhythm of 
aldosterone and the assumption that salivary aldosterone concentrations are a useful indicator of 
circulating aldosterone levels. 
More frequent sampling from healthy volunteers which was carried out between the 
hours of 8:45am and 15:45pm did not show any diurnal rhythm.  This may have been because 
4pm is not late enough to detect the daily diurnal decrease in concentrations, or alternatively, that 
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the more constrained nature of the study, where participants remained in the clinic throughout 
the frequent sampling period in order to collect simultaneous plasma samples, kept levels of 
aldosterone elevated due to stress or other unknown factors.   
In PA patients who collected samples from 8am until midnight there was no observed 
diurnal rhythm. Paradoxically, levels seemed to increase in the evening and deviated more from 
the mean though this was not statistically significant.  Data on the circadian rhythm of 
aldosterone, or lack thereof, in PA patients of any of the subgroups is scarce.  Several studies 
exist, though with conflicting results, describing the influence of pathological changes in the 
RAAS on diurnal rhythms of blood pressure and whether those correlate with levels of 
aldosterone.  Evidence from one study suggests that while patients with APA have a preserved 
circadian blood pressure, as opposed to those with IHA, aldosterone levels do not correlate with 
the blood pressure changes (Zacharieva et al., 2006).  The APA, though largely autonomous in 
its aldosterone secretion, is still influenced by ACTH and subsequently its diurnal rhythm and its 
secretion is synchronous with cortisol fluctuations regardless of changes in posture (Kem et al., 
1973).   Mean values from the patients with a diagnosis of PA due to an APA who were included 
in the studies shown here however, did not show a diurnal rhythm in aldosterone concentrations 
although there was a clear response to the ACTH injection. 
 
4.4.2.  Posture test findings and future application 
The studies demonstrated overall that it was possible to apply the assay for measurement 
of aldosterone in saliva in order to monitor plasma aldosterone levels.  The results correlated 
positively to plasma at 28%, in accordance with previous literature, mirroring its fluctuations 
under physiological conditions.  An ideal setting to monitor a more drastic increase in 
aldosterone, typically used in clinical settings to study the responsiveness of the adrenal gland 
and distinguish the subtype of primary aldosteronism, is the posture test.  The posture study was 
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used to demonstrate further that saliva as a medium can monitor aldosterone concentration 
reliably and that patients suspected of primary aldosteronism could potentially carry out this type 
of testing unsupervised in an out patient basis by collecting salivary samples instead and thereby 
avoiding the necessary admission to the clinic. 
The study provided further potentially useful information in that females who 
participated in the study had a significantly higher aldosterone response to change in posture than 
males, in both plasma and saliva, and that the males reached mean peak aldosterone values an 
hour later than the females.  The higher increase in the females could not be explained however 
by increased stimulation of the RAAS in these participants because this difference was not also 
observed in the renin results (data not shown).  A clear sex difference that has been reported in 
both rats and humans is that there is a greater sensitivity of the adrenals to ACTH in females than 
in males, and this was also supported by our data where males had higher levels of ACTH 
following posture than females and may explain the higher response in aldosterone levels in the 
females (ACTH data not shown).  Though this sex difference in response to posture has 
previously been reported in plasma values (Vernikos et al., 1993) it had not been shown before in 
studies involving salivary sample collection and serves as a further confirmation that gender 
differences should be taken into account when carrying out posture testing.   
Another important finding was that the smokers taking part had higher salivary 
aldosterone throughout the duration of the study, as well as a higher increase compared to basal 
levels just before the change in posture.  This was not seen, however, in the plasma values.  It 
has also been well documented that chronic exposure to cigarette smoking brings about 
alterations in the responsiveness of the HPA axis, mainly due to the effects of nicotine, and 
additionally that smokers have higher free cortisol levels than non-smokers (Kirschbaum & 
Hellhammer, 2006).  In our study we did not examine salivary cortisol concentrations but this 
would enhance the observations found in salivary aldosterone.  The smokers also had higher 
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increases in ACTH following posture which were highly correlated to the increases in 
aldosterone (data not shown) and this is in agreement with the findings of previous workers such 
as Baer et al in 1985.   Other studies report enhanced activation of the RAS in smokers 
(Laustiola et al., 1988) but this was not replicated in our study where smokers did not have 
higher renin levels than non-smokers.  (A short study which was conducted in our laboratory to 
see if smoking affects salivary aldosterone levels due to changes in flow rate showed that this 
was not the case and that this is rather a long term effect.)  We conclude that it is most likely that 
the increased ACTH, due to increased HPA axis activation and levels of cortisol, brings about 
higher levels of free aldosterone due to the decreased binding availability of aldosterone to CBG.  
Similar circumstances have previously been shown with aldosterone levels, after increased 
cortisol concentrations due to stimulation with ACTH (McVie et al., 1979).   
 
4.4.3.  ACTH stimulation test findings and future application  
Not many studies exist describing the normal salivary responses of aldosterone to ACTH 
stimulation.  The study by Cardoso et al in 2002 showed mean peak values of 193pmol/l 
(67pg/ml) at 60 minutes with a dose of 250µg synthetic β1-24 ACTH, whereas Few et al in 1984 
showed a peak of approximately 50pmol/l (18pg/ml) but with a lower dose of only 50µg ACTH.  
In our study the peak values after ACTH stimulation in healthy subjects were at a mean of 128 
±19pg/ml (358pmol/l) at 75 minutes with 250µg synthetic β1-24 ACTH.  Peak responses were 
also mirrored in the paired plasma samples which were collected concurrently.  As far as we are 
aware there is no published data for salivary aldosterone levels in PA patient following 
stimulation with ACTH.  Salivary aldosterone levels continued to increase for the 30 minutes 
following the peak seen in plasma levels in the PA patients, which could be explained by the 
overall higher levels of aldosterone giving rise to higher free concentrations due to decreased 
possibility of attachment to binding proteins.  This information may be clinically useful to 
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delineate the total time necessary for collection of samples after the stimulation test, and 
potentially allowing for a diagnosis of adrenal function through the assessment of the salivary, 
free, active fraction of plasma aldosterone.  The study reinforced the findings of previous 
investigations showing that in control subjects maximum responses will be found at 100 minutes 
following administration of corticotropin hormone (Cardoso et al., 2002).    
 
4.4.4.  Aldosterone to cortisol ratio – confirmation for diagnosis of PA 
There is no reported set ratio between aldosterone and cortisol in saliva for healthy or 
aldosteronism individuals.  Studies have shown that salivary glucocorticoids are positively 
correlated with salivary aldosterone levels (Kooner et al., 1991) and that the two hormones are 
more closely correlated during later periods in the day when fluctuations in aldosterone are 
smaller (Few et al., 1987).  The preliminary data we have produced from twenty-seven PA 
patients and forty-one healthy controls suggest that using our assay combination a value of 0.1 
for this ratio at basal physiological conditions in the evening may be used as a cut off for 
diagnosis of excess aldosterone production, as in the case of primary aldosteronism.  During 
stressful situations such as was demonstrated by the extreme example of ACTH stimulation, 
however, the ratios decline in both groups, mainly due to the dramatic increase in cortisol which 
is less pronounced in aldosterone and renders the ratio inadequate.  For this reason, combined 
with the normal diurnal decrease in cortisol in the evening, sampling for determination of the 
ratio to differentiate between aldosteronism and healthy individuals is proposed to take place in 
the evening between 6 and 10pm.  The feasibility of using this ratio as a tool for the diagnosis of 
suspected Conn’s syndrome is enhanced by a recent study where authors applied the aldosterone 
to cortisol ratio in serum for the distinction between aldosterone-producing adenoma and 
idiopathic hypertensive patients (Giacchetti et al., 2006). 
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4.4.5.  Monitoring fluctuations of aldosterone in rodent plasma – potential for use in an 
experimental setting 
In the second part of this thesis, three animal models were used to validate the 
aldosterone assay using the monoclonal antibody by using small volumes of serum or plasma to 
establish the measurement of aldosterone at physiological conditions, at various stages of pre- 
and post- pubescent development in mice, and after pharmacological and dietary manipulation of 
the HPA axis and the adrenal RAAS, respectively.   
Values for serum aldosterone in mice are reported which are well within the measurable 
range of this assay.  After assessment of samples taken from seventy-five C57BL/6 x NMRI 
mice we found no gender-dependent difference.  This observation included male and female 
mice aged between 3 and 11 weeks after birth.  To our knowledge so far, there has been no in-
depth study describing gender-related levels of aldosterone in these or any other strain of mice.  
Though extragenital differences in mouse organs such as kidney, liver, and skeletal muscle are 
known to exist and differences in mouse adrenal weights have been reported, the exact nature of 
the differences within the adrenal gland have not as yet been established (Bastida et al., 2007).  
For example in one recent study (Sausbier et al., 2005) no differences were found in aldosterone 
levels between male and female wild type mice (SV129/C57BL6) and mice with mutations in 
voltage- and Ca2+-dependent potassium channels.  In another study looking at polyamines and 
adrenal sex dimorphisms however, female mice were found to have significantly higher basal 
aldosterone levels than male mice of the same (CD1) strain (Bastida et al., 2007). 
Other authors have previously reported findings (Zhang et al., 2003; Jensen et al., 2004), 
that aldosterone does not change significantly in rodents during postnatal development, however 
these experiments were carried out in rats.  In the present investigation we observed a highly 
significant increase in the levels of aldosterone between five and seven weeks of age and, though 
these levels decreased at weeks 9 and 11, they remained at a significantly higher level when 
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compared to 3- and 5-week-old mice.  No difference in plasma aldosterone concentrations 
between neonate and adult 3-month-old mice (C57BL/6 strain) were reported by Cao et al (Cao 
et al., 2006).  As mice older than 11-weeks were not included in the study, it is possible that the 
aldosterone levels decline thereafter.  In another study showing aldosterone levels in 1 week- and 
1 month-old wild-type and proopiomelanocortin (POMC) null animals, the authors reported 
aldosterone levels which were approximately twice as high in the wild types at 1 month 
compared to 1 week (793 ± 103 vs 357 ± 145 pg/ml) and significantly decreased at one month 
(203 ± 39 pg/ml) in the POMC null mice, while no difference occurred between wild-type and 
mutant mice at week 1 (89 ± 5 pg/ml) (Karpac et al., 2005).  However, the different strain, assay, 
and blood sampling techniques used hamper a comparison between those studies and our own. 
In order to show that the assay can be used to reflect changes in adrenocortical function 
after pharmacological or diet induced interventions in mice, aldosterone levels were investigated 
after suppression or stimulation of the HPA axis with dexamethasone and ACTH and after 
stimulation of the adrenal RAS by varied potassium diets.  Aldosterone responses to ACTH 
stimulation compared to basal values have not been extensively documented so far in wild type 
mice.  One study describes the response to ACTH treatment in wild type mice and mice lacking 
POMC, the precursor for ACTH, whereby the size of the adrenal gland as well as missing zonal 
structure, including the zona glomerulosa, returns after the 10 day treatment, with corticosterone 
levels rising in POMC null mice (to equal sham treated wild types) whilst aldosterone levels 
remain un-stimulated (Coll et al., 2004).  However aldosterone data is not presented in this 
article describing the wild type values for response to ACTH.  In the 11 week old mice which 
were included in the study assessing the response of the HPA axis, concentrations following 
stimulation with ACTH were, as expected, significantly higher compared to controls while those 
treated with dexamethasone suppression had concentrations significantly lower than the control 
group.  Though ACTH was administered over ten days in these animals, the data most probably 
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demonstrate the effect of the last dose of ACTH on levels of aldosterone.  This is most likely the 
case since studies have shown that ACTH has only short-lived effects on aldosterone, with a 
half-life of only 8 minutes, and the response to stimulation with ACTH decreases during chronic 
treatment unless it is given in a pulsatile fashion (Seely et al., 1989). 
Elevated extracellular potassium concentrations directly stimulate aldosterone production 
by acting on the steroidogenic pathways occurring in the cells of the zona glomerulosa.  This 
happens in a rapid effect within minutes at the level of cholesterol conversion to pregnenolone, 
but also on a longer-term basis of hours to days, by increased activity of aldosterone synthase at 
the level of corticosterone conversion to aldosterone (Muller, 1995; Williams, 2005).  In our 
assessment of serum samples from mice administered a high K+ diet for 5 weeks aldosterone 
levels were greatly increased as expected.  The extent of the increase was confirmed as results 
were in extremely close correlation with a commercial assay requiring a much larger sample 
volume. Concentrations were not suppressed, however, on a low K+ diet to below the control 
group values, and this was also observed using both assays.  The findings of aldosterone levels in 
wild type mice on a normal potassium diet are in agreement with the findings of previous authors 
(172 ± 36 pg/ml vs 201.8 ± 26.2 pg/ml) (Arrighi et al., 2001), however the concentrations after a 
high K+ diet are significantly lower but this may be expected as the mice were only given high 
K+ chow without concurrently increased amounts of K+ in the drinking water and the diet was 
only given for 2 weeks as opposed to 5 weeks as was the case in our study.  
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5.  Summary 
Recent evidence has shown the increased incidence of PA in approximately 15% of the 
hypertensive population, making a non-invasive and simple screening method for the 
measurement of aldosterone levels necessary.  The use of saliva for determination of steroid 
hormones is now widely used and accepted and salivary aldosterone concentrations have 
previously been reported at around 30% of those seen in plasma.  Furthermore, there is a current 
lack of longitudinal and systematic studies addressing the involvement of aldosterone in the 
regulation of the RAAS in rodents due to sample volume restrictions and the lack of sensitivity 
to detect the very low aldosterone concentrations in commercially available assays.  
We developed a non-isotopic, competitive immunoassay for the determination of 
aldosterone levels in saliva, as well as in human and mouse plasma samples.  The assay employs 
an aldosterone-biotin conjugate as the tracer and end-point determination through time-resolved 
fluorescence (TR-FIA) with Streptavidin-Europium as the detectable label. No pretreatment or 
purification of saliva is necessary while a simple extraction step is incorporated for the 
assessment of plasma levels. A polyclonal antibody was used for the development of the saliva 
assay giving a lower limit of detection of 19 pg/ml for each 50µl sample.  Similarly, a highly 
specific monoclonal antibody against aldosterone, exhibiting a more sensitive linear working 
range starting from 8 pg/ml is used to detect aldosterone in 50µl of plasma.  The monoclonal 
antibody could potentially also be used for the determination of salivary aldosterone levels, 
however this was not sufficiently evaluated in the studies shown here and further investigation of 
the exact assay conditions is needed. 
Inter- and intra-assay coefficients of variation, mean recoveries, accuracy and linearity 
were validated for both assays and the assay results correlated significantly with a commercially 
available radioimmunoassay for plasma in both settings. 
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Overall, salivary aldosterone was found to correspond to approximately 28% of the 
concentrations seen in plasma and reflected the changes seen with posture and ACTH 
stimulation accurately. The assay presents the additional possibility of using salivary aldosterone 
levels, in combination with salivary cortisol, as a diagnostic tool in a clinical setting to screen 
suspected cases of PA and exclude healthy subjects.  The salivary aldosterone to cortisol ratio 
remains elevated in PA persons due to autonomous hypersecretion of aldosterone throughout the 
day, alongside decreasing levels of cortisol, and can be clearly distinguished from healthy 
persons above a cut-off level of 0.1.  Furthermore, as aldosterone concentrations are acutely 
affected by ACTH it was determined that sampling for this test should be carried out in the 
evening to avoid stress factors as well as diurnal fluctuations. 
In addition, as basal aldosterone values and those after suppression and stimulation under 
different conditions were found within the linear range of the assay, it is proposed that the assay 
could be especially useful to monitor adrenocortical function in pharmacological and dietary 
intervention studies in rodent models where repeated sampling and volumes collected are limited 
and measurement of multiple blood parameters is desirable. 
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Zusammenfassung 
 
 
Neue Untersuchungen zeigten, dass bei hypertensiven Patienten die Inzidenz des primären 
Hyperaldosteronismus höher als lange angenommen ist und bis zu 15% beträgt. Deshalb ist eine 
nichtinvasive und einfach durchzuführende Untersuchungsmethode zur Messung der 
Aldosteronkonzentration erstrebenswert. Die Verwendung von Speichel für die Bestimmung 
vieler Steroidhormone ist mittlerweile verbreitet und akzeptiert. Aldosteron zirkuliert in sehr 
niedrigen Konzentrationen im Plasma, und die Konzentration von Aldosteron im Speichel 
beträgt nach einzelnen Berichten ungefähr 30% der Plasmakonzentration. Daher ist die 
Sensitivität verfügbarer Aldosteronassays zur Messung im Speichel nicht ausreichend. Ein 
ähnliches Problem ergibt sich bei Studien, die den Einfluss von Aldosteron auf die Regulation 
des RAAS in Nagern untersuchen, da hier das Probenvolumen limitiert ist und kommerziell 
erhältliche Assays nicht sensitiv genug sind, um hier die sehr niedrigen 
Aldosteronkonzentrationen zu messen. 
 
Daher wurde im Rahmen dieser Arbeit zunächst ein hochsensitiver, nicht-isotopischer 
kompetitiver Immunoassay zur Bestimmung der Speichelaldosteronkonzentration entwickelt. 
Der Assay verwendet ein polyklonales Antiserum als Fangantikörper und ein Aldosteron-Biotin 
Konjugat als Tracer, die Endpunktbestimmung erfolgt über Streptavidin-Europium durch 
zeitaufgelöste Fluoreszenz (TR-FIA). Für diesen Assay ist bei Speichelproben keine 
Vorbehandlung oder Reinigung notwendig, bei einem Probenvolumen von 50 µl wird ein unteres 
Detektionslimit von 19 pg/ml erzielt. Eine Abwandlung dieses Assays unter Verwendung eines 
spezifischen monoklonalen Antikörpers gegen Aldosteron erlaubt nach einer einfachen 
Extraktion mit Dichlormethan auch die Aldosteronbestimmung in kleinsten Volumina von 
humanem und murinem Plasma. Hierbei wird bei 50 µl Probenvolumen eine Sensitivität von 8 
pg/ml erreicht. Ob dieser monoklonale Antikörper auch für den Speichelassay genutzt werden 
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könnte, wurde im Rahmen der hier gezeigten Untersuchungen noch nicht im Detail evaluiert. Die 
technische Validierung beider Assays wurde hinsichtlich Präzision, Reproduzierbarkeit, 
Wiederfindung, Linearität und Kreuzreaktivitäten durchgeführt. Die Meßergebnisse beider 
Assays korrelierten signifikant mit denen eines kommerziell erhältlichen Plasma-
Radioimmunoassays, der allerdings ein vielfach höheres Probenvolumen benötigt. 
 
Die klinische Validierung des Speichelassays bestätigte, daß die 
Speichelaldosteronkonzentration ca. 28% der Plasmakonzentration beträgt. Effekte durch 
Positionsveränderungen und ACTH-Stimulation, die sich im Plasmaaldosteron zeigen, werden 
akkurat auch in der Speichelaldosteronkonzentration widergespiegelt. Zudem wurde die 
Möglichkeit evaluiert, durch parallele Bestimmung von Aldosteron und Cortisol im Speichel und 
die Berechnung des Aldosteron/Cortisol-Quotienten Patienten mit primärem 
hyperaldsoteronismus von gesunden Subjekten abzugrenzen. Der Aldosteron/Cortisol-Quotient 
ist bei Patienten insbesondere spät nachts erhöht, da die autonome Hypersekretion von 
Aldosteron anhält, während die Cortisol-Werte absinken. Bei einem cut-off-Wert für den 
Quotienten von 0,1 können Patienten eindeutig von Gesunden unterschieden werden. Da die 
Aldosteron-Konzentration auch durch ACTH erheblich beeinflußt wird, wurde die abendliche 
Probennahme als bester Zeitpunkt ermittelt, da hier in aller Regel Streß und andere hypophysär 
vermittelte Einflußfaktoren am geringsten sind. 
 
Der Assay zur Messung von Aldosteron aus kleinsten Probenvolumina wurde im Nagermodell 
validiert, wobei Werte nach Suppression der Nebennieren mit Dexamethason wie nach 
Stimulation mit ACTH und Kochsalzrestriktion innerhalb des linearen Messbereichs lagen. 
Deshalb könnte der Assay gerade im Nagermodel besonders nützlich sein, um die 
adrenocortikale Funktion in pharmakologischen und diätetischen Interventionsstudien zu 
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untersuchen. Angesichts der limitierten Probenvolumina gerade bei wiederholten Blutabnahmen 
sowie dem Bedarf, eine Vielzahl verschiedener Blutparametern zu bestimmen, sind bislang 
verfügbare Aldosteronassays hier wenig geeignet. 
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7.2. Questionnaire for Posture Study Test  
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